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Background & Aims: Cirrhosis and chronic inflammation precede development of 
hepatocellular carcinoma (HCC) in approximately 80% of cases. We investigated 
immune-related gene expression patterns in liver tissues surrounding early-stage HCCs 
and chemopreventive agents that might alter these patterns to prevent liver 
tumorigenesis. 
 
Methods: We analyzed gene expression profiles of non-tumor liver tissues from 392 
patients with early-stage HCC (training set, n=167 and validation set, n=225) and liver 
tissue from patients with cirrhosis without HCC (n=216, controls) to identify changes in 
expression of genes that regulate the immune response that could contribute to 
hepatocarcinogenesis. We defined 172 genes as markers for this deregulated immune 
response, which we called the immune-mediated cancer field (ICF). We analyzed the 
expression data of liver tissues from 216 patients with cirrhosis without HCC and 
investigated the association between this gene expression signature and development 
of HCC and outcomes of patients (median follow-up 10 years). Human liver tissues were 
also analyzed by histology. C57BL/6J mice were given a single injection of 
Diethylnitrosamine (DEN) followed by weekly doses of carbon tetrachloride to induce 
liver fibrosis and tumorigenesis. Mice were then given orally the multiple tyrosine inhibitor 
nintedanib or vehicle (controls); liver tissues were collected and histology, transcriptome, 
and protein analyses were performed. We also analyzed transcriptomes of liver tissues 
collected from mice on a choline-deficient high-fat diet, which developed chronic liver 
inflammation and tumors, given orally aspirin and clopidogrel or the anti-inflammatory 
agent sulindac vs mice on a chow (control) diet.  
 
Results: We found the ICF gene expression pattern in 50% of liver tissues from patients 
with cirrhosis without HCC and in 60% of non-tumor liver tissues from patients with early-
stage HCC. The liver tissues with the ICF gene expression pattern had 3 different 
features: increased numbers of effector T cells; increased expression of genes that 
suppress the immune response and activation of transforming growth factor beta 
signaling; or expression of genes that promote inflammation and activation of interferon 
gamma signaling. Patients with cirrhosis and liver tissues with the immunosuppressive 
profile (10% of cases) had a higher risk of HCC (hazard ratio, 2.41; 95% 1.21–4.80). 
Mice with chemically-induced fibrosis or diet-induced steatohepatitis given nintedanib or 
aspirin and clopidogrel downregulated the ICF gene expression pattern in liver and 




Conclusions: We identified an immune-related gene expression pattern in liver tissues 
of patients with early-stage HCC, called the ICF, that associates with risk of HCC 
development in patients with cirrhosis. Administration of nintedanib or aspirin and 
clopidogrel to mice with chronic liver inflammation caused loss of this gene expression 
pattern and developed fewer and smaller liver tumors. Agents that alter immune 
regulatory gene expression patterns associated with carcinogenesis might be tested as 
chemopreventive agents in patients with cirrhosis. 
 
 





Liver cancer is the fourth leading cause of cancer-related mortality worldwide1. 
Hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers and is the 
main cause of death in patients with cirrhosis2,3. HCC arise from chronic liver 
inflammation, fibrosis and eventually cirrhosis in 70-80% of cases2. In developed 
countries, curative treatments are feasible in 30-40% of cases, but recurrence is high 
and no effective adjuvant therapies are available2,4. In addition, ~40-50% of patients are 
diagnosed at advanced stages when currently approved molecular therapies yield limited 
survival benefits (~1 year)3. Despite recent advances in the management and clearance 
of HCV infection, there is an unmet need for early detection and application of 
chemopreventive approaches in patients at high-risk of HCC development. 
To date, there are no established preventive strategies for HCC in patients at risk beyond 
prevention with anti-viral therapies5. Once cirrhosis is established, anti-viral therapies 
reduce but do not eliminate the risk of HCC4,6,7. Individual risk assessment is a key first 
step in the successful development of any chemopreventive strategy. In this regard, 
increasing evidence suggests the existence of the so-called “cancer field-effect” or field 
cancerization which consists of predisposing oncogenic and inflammatory signals 
occurring during chronic liver injury and ultimately leading to malignant transformation8–
10. Gene signatures derived from the cirrhotic tissue adjacent to HCC tumors have been 
designed  to predict poor outcome, particularly in HCV-infected cirrhotic patients at 
higher risk of HCC development9,11–14. Overall, these studies support the feasibility of 
using molecular scores of the carcinogenic field to identify patients at high risk of HCC 
development. However, the carcinogenic roles of inflammation and immune response in 
the context of the field cancerization have been poorly explored. Understanding the 
immune features governing the unresolved cancer field-effect is crucial for identifying 
potential therapeutic targets in patients at high risk of HCC development. 
In this study, the analysis of the inflammatory milieu that characterizes the underlying 
liver disease in which HCC tumors arise has led to the identification of an immune-
mediated cancer field (ICF) in 60% of early HCC patients and 50% of cirrhotic patients 
without HCC. This ICF comprises three distinct molecular subtypes including the High 
Infiltrate ICF subtype with increased infiltration of effector T cells, the 
Immunosuppressive ICF subtype with activation of stroma and TGF-b signaling, and the 
Pro-inflammatory ICF subtype with up-regulation of IFN-g signaling. These immune 
profiles, particularly the Immunosuppressive cancer field, predict increased risk of HCC 
development in cirrhotic patients. Inhibition of this carcinogenic field significantly reduced 
HCC onset in two mouse models of chronic liver damage and hepatocarcinogenesis. 
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Overall, our study provides the rationale to explore chemopreventive strategies in 






MATERIALS AND METHODS 
Human cohort 
Gene expression data from a cohort of 167 surgically resected fresh-frozen samples 
(Heptromic dataset, GSE63898) with matched tumor and adjacent non-tumor tissue 
were analyzed. Samples were previously collected (1998-2008) in the setting of the HCC 
Genomic Consortium upon institutional review board approval. Full description of the 
cohort and RNA profiling data are available in previous publications15,16. Supplementary 
Table 1 provides a summary of the clinical-pathological variables of the samples used in 
the current study (training cohort, n=167). Validation of the identified molecular profiles 
was then performed in an independent set of 225 adjacent non-tumor liver tissues 
previously characterized by our group (GSE10143)9. Finally, to identify those non-
neoplastic patients at higher risk of HCC development and most likely to benefit from 
chemopreventive strategies, our findings were evaluated in a previously characterized 
cohort of patients with early cirrhosis (n=216, GSE15654)14 and a publicly available 
dataset of fibrotic liver tissues (n=124, GSE84044)17. 
 
Modeling the immune-mediated cancer field 
Enrichment scores of 4872 gene sets that represent cell states and perturbations of the 
immune system (Collection C7 of MSigDB, Broad Institute)18 were calculated by Single-
sample Gene Set Enrichment Analysis (ssGSEA) in the non-tumor liver tissue of the 
training cohort. Next, unsupervised clustering analysis by non-negative matrix 
factorization (NMF consensus)19 method was performed to identify the presence of an 
immune-mediated cancer field. To characterize the samples presenting an ICF and to 
identify different immune-mediated field subtypes, a second unsupervised clustering was 
performed using ssGSEA scores obtained for a curated set of gene signatures 
representative of individual cell types20,21 ,cancer immune-related signaling pathways22, 
and inflammation- or immune-specific biological processes (Hallmark collection of 
MSigDB, Broad Institute).  
 
Generation of an immune-mediated field gene signature 
An ICF field gene signature was generated using top differentially expressed genes in 
each molecular group (FDR<0.05; Fold-change ≥2), which was then validated in an 
independent dataset using Nearest Template Prediction (NTP) analysis (p-value<0.05) 





Molecular characterization of the ICF subtypes and identification of candidate 
therapies 
To characterize the ICF subtypes, gene expression signatures [available in MSigDB 
(Broad Institute) or previously reported (Supplementary Table 2)] were assessed by 
GSEA, ssGSEA, NTP and Ingenuity Pathway Analyses (IPA). CIBERSORT20 was used 
to estimate the relative fraction of 22 immune cell types within the leukocyte compartment 
of non-tumor liver tissues. The Immunophenoscore (IPS) algorithm24 was used to 
analyze the major immunogenic determinants. An in silico analysis based on ssGSEA 
scores of ~1230 gene sets (DSigDB) recapitulating targets of approved therapies was 
also performed for the screening of candidate targeted therapies.  
 
Histological evaluation of infiltrating inflammation 
Histopathological analysis was performed in 98 out of 167 cases. Specifically, 
hematoxylin and eosin (H&E) staining of formalin-fixed paraffin embedded (FFPE) tissue 
section of HCCs and their matched adjacent non-tumor livers were evaluated by two 
expert pathologists (CM and MS). The presence of inflammation (portal/septal, interface, 
pericentral and lobular) as well as the lymphoid aggregates were assessed in the non-
tumor liver tissue sections. More details on the histological evaluation of the samples 
have been included in Supplementary material. 
 
Animal models  
We generated a chemically-induced model of HCC and fibrosis in male C57BL/6J mice 
(Harlan Laboratories, n=55) by a single injection of Diethylnitrosamine (DEN) followed 
by weekly dosing with carbon tetrachloride (CCl4), as previously described25. Once 
fibrosis was established, mice were randomized to receive vehicle or nintedanib (50 
mg/kg, Boehringer Ingelheim). Mice were sacrificed at different time-points and liver and 
tumor tissue samples were collected and processed for histological, transcriptomic and 
protein expression analyses (see Supplementary material). All experimental 
procedures were carried out following the approval of the institutional ethical committee 
of the University of Barcelona and Hospital Clinic of Barcelona. Additionally, liver 
samples of a choline-deficient high-fat diet (CD-HFD) fed mouse model reported in a 
recent study26 were collected. A total of 25 samples were processed for transcriptomic 
profiling, including mice fed a chow diet (n=5) or CD-HFD for 12 months and given: 







All analyses were performed using SPSS software version 23 (IBM) or GraphPad Prism 
version 5.00 (San Diego, CA). Correlations for categorical and continuous variables were 
analyzed by Fisher’s exact test and Wilcoxon rank-sum test, respectively. The prognostic 
value of the signatures was assessed using Kaplan-Meier estimates, log-rank test, and 
Cox regression models. In in vivo studies, the Mann-Whitney U test was used to compare 
differences in body weights, liver function, tumor number, tumor size and CD4/CD8 
stained area in human samples. Fisher exact test was performed for analysis of HCC 
incidence and pERK staining. Student T-Test was used to compare the differences in 
Sirius Red quantification, CD31 staining, CD4/CD8 staining proportion of immune cell 




Identification of a novel immune-mediated cancer field effect in non-tumor liver 
tissue of patients with early HCC.  
In order to characterize the immune features governing the unresolved cancer-field in 
which new cancers arise, transcriptome-based analysis of a compendium of ~5,000 
annotated immunology-specific gene-sets18 was performed in the non-tumor liver tissue 
of patients with early stage HCC. This analysis revealed the presence of an immune-
mediated cancer field (ICF) in ~60% (98/167) of samples (Figure 1A and 
Supplementary Figure 1). Specifically, these samples were characterized by 
enrichment of several gene-sets recapitulating the presence of activated immune cells, 
up-regulation of core signaling pathways involved in immune response (both innate and 
adaptive) as well as those involved in the modulation of inflammatory response (i.e. IL2-
STAT5, IL6-STAT3, IL17, IFN-γ, CSF, TNF-α, and TGF-β signaling) (Figure 1A-B and 
Supplementary Figure 1). Moreover, histological evaluation confirmed that liver tissues 
with ICF contained a higher frequency of moderate to marked inflammatory infiltrate 
(74% in ICF vs. 52% in non  ICF, p=0.034) and lymphoid aggregates (80% in ICF and 
vs. 55% in non ICF, p=0.009) (Figure 1C-1D and Supplementary Table 3). 
Immunostaining for CD4+ and CD8+ further confirmed significantly higher levels of T cell 
infiltrates in the adjacent livers of patients with the ICF (Supplementary Figure 2A). In 
contrast, histological evaluation of the tumor showed no significant correlation between 
the presence of the ICF and the detection of intratumoral or peritumoral infiltration 
(Supplementary Table 3). This is in accordance with our recent publication15, where the 
tumor immune-based profile did not correlate with presence or absence of immune gene 
signatures in the surrounding non-tumor tissue.  
While characterizing the ICF we detected that, in addition to immunogenic features, 
several well-known carcinogenic signals such as epithelial-to-mesenchymal transition, 
KRAS, EGFR, and VEGF signaling were also significantly enriched in liver tissues 
containing the ICF (Supplementary Table 4). In line with these oncogenic signals, a 
significant enrichment of previously reported prognostic signatures derived from the 
adjacent non-tumoral liver were also detected. These signatures included the 186-gene 
cancer-field signature9, activated hepatic stellate cells (HSCs)11, hepatic injury and 
regeneration (HIR)13, and multicentric occurrence of HCCs27 (Figure 1A). The presence 
of the ICF significantly correlated with HCV infection, features indicative of liver 
dysfunction such as high bilirubin, low platelet count and albumin levels (Supplementary 
Table 5) and poor survival [median OS 43.4 mo in the ICF group vs 94.8 mo in non ICF; 
p=0.001], (Supplementary Table 6 and Supplementary Figure 1B). Altogether, our 
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data highlight the presence of an immune-mediated cancer field in 60% of early HCC 
patients. This ICF is characterized by activation of immunomodulatory signaling 
cascades (i.e. IFN-γ, TNF-α, TGF-β, IL6) along with cancer promoting signaling 
pathways (i.e. EMT, EGFR and VEGFR), and is associated with HCV infection and poor 
prognosis. 
 
The immune-mediated cancer field contains 3 distinct molecular subtypes. 
Further dissection of the key immune-modulating signaling pathways and immune-cell 
infiltrates in those samples harboring the immune-mediated cancer field revealed the 
existence of three distinct molecular subtypes. The first molecular subtype, henceforth 
called the “High Infiltrate ICF” subtype (23% of the ICF), showed a significant enrichment 
of several previously established gene signatures mirroring the presence and/or 
activation of immune cell infiltrates such as lymphocytes (T and B cells)22,28 or 
macrophages29 (Figure 2A-2B). Consistently, immunogenicity, herein captured either by 
the cytolytic activity score (Figure 2A)30 or using the immunophenoscore algorithm24 
(Figure 2B), was also significantly higher in these samples (p<0.001). Specifically, non-
tumor liver samples belonging to the High Infiltrate ICF subtype showed significant 
infiltration of effector T cells (Figure 2B, p≤0.001), including increased levels of cytotoxic 
CD8+ T cells assessed both by transcriptomic (p=0.03) and immunohistochemistry 
(p=0.0002) (Figure 2C and Supplementary Figure 2B). This subtype also was 
characterized by enrichment of the previously reported ectopic lymphoid structures 
(ELS) signature31 (Figure 2A). In addition, the High Infiltrate ICF was significantly 
associated with poor survival in comparison to the rest of the patients (Supplementary 
Figure 1C), although there were no significant differences among the distinct ICF 
subtypes (Supplementary Figure 1D). The second subtype, the so-called 
“Immunosuppressive ICF” (36% of the ICF), was characterized primarily by activation of 
stroma and HSCs, increased TGF-β signaling and T cell exhaustion (Figure 2A). 
Moreover, several immune-checkpoints (i.e. CTLA-4, TIGIT, LAG3) were significantly 
over-expressed (IPS, p<0.01) in this class, along with higher levels of M2 macrophages 
(p=0.04) and CD4+ memory resting cells (p=0.005), which are among main mediators of 
immune tolerance and inhibition (Figure 2B-2C). The third subtype (41% of the ICF) 
showed a clear predominance of IFN-γ signaling (p<0.001) and enrichment of the 
inflammatory M1 macrophages (p<0.0001), and was called the “Pro-inflammatory ICF” 
subtype (Figure 2A-2C). Interestingly, the High Infiltrate and Immunosuppressive 
subtypes shared several molecular features including the enrichment of key signaling 
pathways involved in modulating the immune response (i.e. IL2 and TNF signaling), 
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proliferation (i.e. KRAS signaling) and angiogenesis (Figure 2A, p<0.001).  
In order to further confirm the presence and molecular traits of the identified ICF, we 
generated a transcriptome-based gene signature able to capture the three immune-
mediated cancer field subtypes. Interestingly, this signature only showed minimal 
overlap (0-5%) with previously reported gene signatures of field cancerization in HCC 
(Supplementary Figure 3)9,12,14,32. The resulting 172-gene signature (Supplementary 
Table 7) was then validated in the adjacent non-tumor tissue of 225 patients with early 
HCC, previously characterized by our group9,33 (Supplementary Figure 4A). Similar to 
what was previously observed in the training cohort, 58% (130/225) of patients belonged 
to the ICF. Moreover, in this cohort, the presence of the ICF was an independent 
predictor of poor survival [HR=2.73; 95 CI: 1.1-6.8; p=0.03] (Supplementary Figure 4B, 
Supplementary Table 8). Within the ICF group, ~31% (40/130) presented the High 
Infiltrate ICF profile, ~27% (35/130) the Immunosuppressive ICF and ~42% (55/130) the 
Pro-inflammatory ICF subtype (Supplementary Figure 4A). Subsequent molecular 
characterization further confirmed the ability of the signature to capture the main 
molecular traits defining each subtype, such as increased infiltration of effector T cells in 
High Infiltrate subtype, activation of stroma and TGF-b signaling in Immunosuppressive 
subtype and up-regulation of IFN-g signaling in Pro-inflammatory subtype 
(Supplementary Figure 4A). Overall, our results highlight the presence of a poor 
prognosis-related immune-mediated cancer field comprised of 3 molecular subtypes with 
a high degree of lymphocyte infiltration (overall 16% of HCC patients) or predominance 
of either immunosuppressive (overall 20% of HCC patients) or pro-inflammatory (24% of 
HCC patients) signaling cascades.  
 
The immune cancer-field, particularly the immunosuppressive subtype, predicts a 
high risk of HCC development in cirrhotic patients 
Following the identification of an immune-mediated cancer field in the livers of 60% of 
patients with early HCC, we next sought to assess its role in liver disease progression 
and HCC primary occurrence. To this end, the 172-gene signature was analyzed in a 
cohort of 216 non-malignant cirrhotic patients with a median follow-up of 10 years in the 
context of an HCC surveillance program14. Overall, 51% (110/216) of cirrhotic patients 
harbored the ICF, including the High Infiltrate ICF subtype in 28% (31/110), the 
Immunosuppressive ICF subtype in 19% (21/110), and the Pro-inflammatory ICF 
subtype in 53% (58/110) of cirrhotic patients harboring the ICF. Next, we tested the 
capacity of the ICF subtypes to predict the risk of HCC development in cirrhotic patients. 
Interestingly, the presence of the Immunosuppressive ICF subtype (10% of all cirrhotic 
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patients) was significantly associated with a higher risk of HCC development [median 
time to HCC development of 7.4 years (95% CI: 3.2-11.7) vs 17.1 years (95% CI: 10.6-
23.7) in Rest, p<0.0001] and was found to be an independent predictor of HCC 
occurrence in cirrhotic patients in a multivariate analysis [HR 2.41 (95% CI: 1.2-4.8), 
p=0.012] (Figure 3A and Table 1). In addition, the Immunosuppressive ICF was also 
significantly associated with poor survival [median overall survival of 7.1 years (95% CI: 
4.5-9.6) vs 16.3 years (95% CI: 9.1-23.5) in Rest, p<0.0001] and higher risk of hepatic 
decompensation [median time to hepatic decompensation of 6.5 years (95% CI: 4.3-8.6) 
vs >15 years in Rest, p<0.0001] (Figure 3B-3C). Cirrhotic patients harboring the other 
two ICF subtypes (High Infiltrate and Pro-inflammatory subtypes) also showed a non-
significant trend towards a higher risk of HCC development compared to those patients 
lacking the ICF [mean time to HCC development of 12.8 years (95% CI:11.5-14.2) in 
Other ICF subtypes vs 16.3 years (95% CI: 14.2-18.5) in non ICF, p=0.06] 
(Supplementary Figure 5A).  
Moreover, the analysis of an additional cohort of 124 non-neoplastic patients with liver 
fibrosis17 revealed that the immune-mediated cancer field may occur as a progressive 
event, as it significantly correlated with increasing levels of fibrosis stage and degree of 
inflammation (Supplementary Figure 5B). Particularly, the presence of the 
Immunosuppressive ICF significantly correlated with the presence of advanced liver 
fibrosis (Scheuer fibrosis S3-4 score17, p=0.034) (Supplementary Figure 5B).  
In conclusion, the immune-mediated cancer field detected in patients with early HCC is 
also present in the livers of ~50% of cirrhotic patients and captures the presence of a 
damaging and continuous inflammatory response in the underlying liver disease. 
Furthermore, our results underscore the critical role of an Immunosuppressive ICF 
(overall, 10% of cirrhotic patients) in defining a 2.4 risk of HCC development, and to a 
smaller extent of the High Infiltrate and Pro-inflammatory subtypes. 
 
The immune-mediated field as a target for chemoprevention in a mouse model 
recapitulating chronic liver inflammation and HCC development 
Based on the compelling results described above, we hypothesized that the immune-
mediated cancer field, and particularly the Immunosuppressive ICF subtype, may 
represent an ideal target for chemopreventive strategies in cirrhotic patients at high risk 
of HCC development. To this purpose, an in silico-based analysis was performed using 
our training cohort to identify those candidate therapies most likely to modulate the 
identified ICF. This analysis was based on the enrichment of a compendium of ~1230 
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gene sets (DSigDB collections D1 and D2)34 recapitulating the main targets of 1202 
approved drugs. Among the top 10 most significantly enriched drugs (Supplementary 
Figure 6), nintedanib was the only FDA-approved therapy indicated for a non-cancer 
condition. Specifically, nintedanib is the first molecular targeted therapy with clinical 
efficacy in patients with idiopathic pulmonary fibrosis as both an anti-fibrogenic and anti-
inflammatory agent35. Given these considerations, the efficacy of nintedanib in reverting 
the pro-tumorigenic immune-mediated cancer field was tested in a mouse model of HCC 
development in the setting of chronic inflammation and liver fibrosis (Supplementary 
Figure 7A). In this model, the macroscopic evaluation of explanted livers in DEN/CCl4 
mice sacrificed at the age of 15, 17 and 18 weeks confirmed the development of 
numerous hepatic tumors (Figure 4A). Tumor penetrance and number of tumors 
progressively increased, ultimately reaching a 100% incidence at 18 weeks of age 
(Figure 4A and 4B). At all-time points, histological evaluation of the liver sections 
showed that a portion of the tumors were pre-neoplastic (dysplastic) nodules (Figure 
4C). In mice sacrificed at 15 weeks of age, Supplementary Figure 7A), nintedanib 
showed a clear trend towards reducing HCC incidence, number and size of tumors 
(Figure 4B, D and E). These differences reached significance at 17 weeks of age 
(Figure 4B), having a marked decrease in both overall tumor burden (30% in nintedanib 
vs 89% in vehicle group, p=0.019) and specifically in HCC incidence (7% vs 33%, 
p=0.04). Similarly, at 18 weeks of age, HCC incidence was significantly reduced in 
treated mice (Figure 4B, 22% vs 77%, p<0.001). In addition, nintedanib significantly 
reduced the overall tumor number and size both at 17 and 18 weeks of age (Figure 4D-
E). Overall, nintedanib was well tolerated with no significant induction of body weight loss 
or hepatotoxicity measured by serum ALT and AST levels (Supplementary Figure 7B-
C). Taken together, our data suggest that nintedanib is safe and efficacious in preventing 
HCC development in our experimental model. 
 
Nintedanib treatment reverts the immune-mediated cancer field effect  
Next, we sought to assess the impact of nintedanib treatment on the immune-mediated 
cancer field. For this purpose, we analyzed gene expression profiling of non-tumor liver 
samples from 17 weeks-old DEN/CCl4 mice given nintedanib (n= 10) or vehicle (n=9), 
and 3 healthy control mice. First, the comparison between the healthy control group and 
vehicle group revealed a profile of activated pathways compatible with HCC development 
within a fibrotic and inflammatory background. In this regard, functional analysis of 
differentially expressed genes (Supplementary Table 9) highlighted the activation of 
hepatic stellate cells and fibrogenesis, as well as immune system activation 
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(inflammatory response, chemotaxis, binding of myeloid and leukocytes) in vehicle 
treated DEN/CCl4 livers (Supplementary Table 10). Notably, our model presented a 
significant enrichment of the gene-set representing the ICF identified in humans 
(p=0.001) and faithfully recapitulated the human immune-mediated field subtypes 
described above (Figure 5A). The comparison of the gene expression profiles of 
adjacent non-tumor liver from mice treated with vehicle or nintedanib demonstrated that 
nintedanib significantly down-regulated the ICF subtypes and, more specifically the Pro-
Inflammatory and the Immunosuppressive ICF phenotype, which predict risk of HCC 
development in cirrhotic patients (Figure 5A, p=0.02). A non-significant trend was also 
observed for the High Infiltration subtype (Figure 5A). Treatment with nintedanib led to 
a significant down-regulation of inflammatory cues (IL-6/STAT3, interferon-a, interferon-
g) and immune-related signaling (IL-2/STAT5 activation, allograft rejection) (Figure 5A). 
Among the infiltrating immune cells, nintedanib significantly reduced the presence of B 
and T cells, activated macrophages, helper T cells and Tregs along with associated 
immune modulators (i.e. IL1, CCL5 and PDL1) (Figure 5A). Despite exhibiting similar 
global levels of inflammatory infiltrates, quantification of CD4 and CD8 positive infiltrating 
lymphocytes by IHC revealed a significant decrease of CD4+ T cells in nintedanib-
treated mice compared to controls (Figure 5B, p<0.05).  
Next, in order to further characterize the chemopreventive effects of nintedanib we 
assessed the activation status of the main nintedanib targets (i.e. VEGFR2 and PDGFR-
β). Western blot of non-tumor liver tissue confirmed that nintedanib blocked the activation 
of VEGFR2 (Figure 5C) and its downstream effectors AKT and ERK (Supplementary 
Figure 8A). Consistently, both liver parenchyma and liver tumors were pERK positive in 
vehicle-treated mice and pERK negative in nintedanib treated mice (Supplementary 
Figure 8B, p<0.05), indicating an anti-proliferative effect of nintedanib as well. Given the 
strong inhibition of VEGFR signaling observed, we next assessed the anti-angiogenic 
effect of nintedanib in DEN/CCl4 mice. In this model, reduced CD31 staining was 
associated with diminished blood vessel area in both liver parenchyma and liver tumors 
of nintedanib-treated mice (Figure 5D). Altogether, these data suggest that nintedanib 
exhibits its chemopreventive effects in part by inducing vascular normalization and 
inhibiting hepatic proliferation. In contrast, no reduction of fibrosis degree, the pro-
fibrogenic signaling pathway PDGFR-β, or collagen markers were detected in the livers 
of nintedanib-treated mice (Supplementary Figure 8C-E).   
Overall, our data confirm that therapeutic targeting of the immune-mediated cancer field, 
accompanied by liver vascular normalization and suppression of hepatic proliferation, 




Immunomodulatory effects of Asp/Clo treatment revert the immune cancer field 
effect and prevent hepatocarcinogenesis in vivo  
To further support the concept of an ICF in promoting HCC development and its 
therapeutic immunomodulation as candidate strategy for chemoprevention, we 
performed gene expression profiling in non-tumor liver derived from the recently 
described mouse model of choline-deficient high-fat diet (CD-HFD) treated either with 
the immunomodulatory combination aspirin/clopidogrel (Asp/Clo) or the anti-
inflammatory sulindac26. Of particular interest, in this model, which presents non-
alcoholic fatty liver-related liver inflammation with various degrees of fibrosis and HCC 
development after 12 months of diet regimen26,36,37, HCC prevention was achieved only 
through the combination of the anti-inflammatory drug, aspirin, clopidrogel -an P2Y12 
inhibitor-, (25% to 0% 12-mo HCC incidence control vs combo respectively, p=0.01)26  
and not sulindac alone (25% to 20%12-mo HCC incidence control vs sulindac, 
respectively, p=ns, data not shown). In the context of our study, comparative analysis 
between the non-tumor liver of healthy control and CD-HFD mice showed a significant 
enrichment of the ICF signature in CD-HFD mice (p=0.002, Figure 5E). Notably, all 3 
ICF subtypes were significantly up-regulated in CD-HFD mice compared to healthy 
controls (Figure 5E) along with the enrichment of signaling pathways regulating 
inflammation (i.e. IL6-STAT3, TNFα), immune infiltration and activation22,28, and 
epithelial-to-mesenchymal transition (i.e. TGFβ, p<0.05). These data were consistent 
with the high intrahepatic influx of metabolically activated CD8+ T cells and NK cells 
(CD3+NK1.1+) measured in CD-HFD fed mice by flow cytometry26. Overall, these data 
confirm the existence of an ICF in an independent model of chronic liver disease further 
suggesting a role in hepatocarcinogenesis. 
Next, we compared the expression profiles of liver samples from CD-HFD vehicle-treated 
mice with CD-HFD mice treated with the combination Asp/Clo (n=6) or sulindac alone 
(n=10). Interestingly, only Asp/Clo, but not sulindac alone, was able to prevent HCC and 
revert the ICF within the liver microenvironment (p=0.05), being the Pro-inflammatory 
ICF subtype the most significantly down-regulated upon treatment (Figure 5B). 
Particularly, based on previous molecular characterization26,  the inhibition of the ICF 
seemed to be accompanied by a significant reduction of the degree of liver damage, as 
well as a significantly reduced number of CD8+ and NKT cells in the liver.  
Overall, these data support the role of the ICF in promoting carcinogenesis, and suggest 
that only those drugs able to simultaneously inhibit several components of the ICF by 
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targeting mitogenic, angiogenic and immunomodulatory kinases (i.e. nintedanib and 




This study represents an in-depth analysis of the inflammatory milieu associated with the 
“field cancerization” in the chronically injured liver, and investigates its clinical 
implications in the prediction and prevention of HCC occurrence in cirrhotic patients.  
The role of the “cancer field effect” in promoting neoplastic transformation has gained 
much interest in recent years and currently an altered microenvironment is considered a 
promoter of cancer8,10. Although, under physiological conditions, inflammation is an 
adaptive response to tissue injury, when the inflammatory stimuli persist, the non-
resolved inflammation contributes to carcinogenesis38,39. In this line, activation of HSC 
as well as certain pathways, such as nuclear factor-KB and TGF-b signaling, have been 
previously associated with liver fibrogenesis, and eventually neoplastic 
transformation9,12. With this study, we move beyond the limits of current knowledge and 
provide a detailed description of the immune microenvironment underlying the field 
cancerization in the liver. To this end, we first characterized the immune profile of the 
non-tumor liver parenchyma of 392 early HCCs and then investigated its role in 
predicting HCC development in 216 cirrhotic patients with long-term surveillance for HCC 
(median of 10 years)14. The analysis revealed that up to 60% of HCCs and 50% of 
cirrhotic patients showed a deleterious immune-mediated response in the surrounding 
tissue, which was associated with impaired liver function, activation of specific oncogenic 
loops, angiogenesis and poor survival. Further characterization identified three distinct 
subtypes with different levels of lymphocyte infiltration and activation of either 
immunosuppressive or pro-inflammatory traits. In particular, the so-called 
Immunosuppressive ICF subtype (~10% of cirrhotic patients) was an independent 
predictor of HCC development, increasing 2.4 the risk of cancer development, whereas 
both the High-Infiltrate and the Pro-Inflammatory subtypes showed a trend towards 
higher risk of HCC occurrence in cirrhosis. The identification of distinct immune subtypes 
reflects the complex role of the immune system in hepatocarcinogenesis, with both an 
activated immune response and an exhausted immune-microenvironment contributing 
to create a pro-tumorigenic environment and increase the risk of HCC development40. 
Reducing the incidence and mortality of HCC requires advances in chemopreventive 
approaches at pre-neoplastic stages, in addition to curative treatment options for early 
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lesions. Universal immunization against HBV and antiviral therapies against HBV and 
HCV have been associated with very reduced HCC risk2,41,42. Once cirrhosis is 
established, the risk of HCC development remains despite achieving a sustained 
virologic response in HCV patients6,7. In addition, the incidence of other risk factors, such 
as non-alcoholic steatohepatitis (NASH), is dramatically increasing2. Thus, alternative 
HCC preventive strategies capable of interfering with molecular hepatocarcinogenesis 
are an unmet need. Furthermore, identifying those patients at high risk of HCC 
development should enable a cost-effective selection of patients most likely to benefit 
from chemopreventive approaches. In this scenario, our results are of clinical relevance 
since the ICF, and specifically the Immunosuppressive subtype, may provide a novel 
companion biomarker to enrich at-risk patients in chemoprevention clinical trials. Given 
these observations, we then sought to investigate if the molecular forces driving such 
cancer field could serve as target for chemopreventive strategies. Hence, we first verified 
that the molecular profiles observed in human cirrhosis were faithfully reproduced in two 
animal models of chronic liver injury. The DEN/CCl4 chemically-induced mouse model 
as well as the recently described NASH-HCC model26 reliably recapitulated the presence 
of a carcinogenic phenotype observed in liver tissues from patients belonging to the 
immune-mediated cancer field.  
In order to identify the most promising candidate therapies for novel chemopreventive 
strategies, we conducted an in silico analysis using a large compendium of gene sets34 
recapitulating the main targets of 1202 approved drugs. Among the top ten most 
significantly enriched drugs, we selected nintedanib, the only FDA therapy approved for 
non-neoplastic conditions. In the DEN/CCl4 animal model, oral administration of 
nintedanib reduced the immune-mediated cancer field, including the 
Immunosuppressive ICF subtype, ultimately reducing HCC incidence and growth. 
Reversion of the ICF induced by treatment with nintedanib was accompanied by 
reduction of CD4+ lymphocytes, which could be due to its mechanism of action inhibiting 
src family of kinases (i.e. LCK, FLT3 and SRC) . These findings are in line with previous 
reports suggesting that CD4+ cells propagate immune-mediated liver injury in models of 
chronic liver inflammation or autoimmune liver disease43,44. Pretreatment with T cell-
specific Abs or immunosuppressive agents, such as anti-CD4 mAb, FK506 (Tacrolimus), 
or cyclosporine A, have shown to ameliorate hepatitis in these models, further supporting 
the role of CD4+ T cells in inducing liver damage43. Results in a second animal model 
treated with the combination of the anti-inflammatory drug, aspirin, and clopidrogel – a 
P2Y12 inhibitor-, confirmed the therapeutic potential of immunomodulating the ICF and 
supported the pro-tumorigenic role exerted by the immune response. Indeed, only the 
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treatment able to modulate the ICF, as indicated by the reduction of immune cells (i.e. 
CD8+ and NKT cells) and the reversion of the ICF signature, successfully reduced liver 
damage and prevented HCC development. Overall, our study identifies a novel 
promising chemopreventive strategy for HCC and confirms the validity of using the 
reversion of the ICF as reliable read-out of efficacy. This is of great clinical importance 
since there is currently no effective method to monitor the short-term effects of 
chemopreventive drugs5. Nintedanib belongs to a new generation of TKIs that, in addition 
to exerting immune modulation blocks the activation of main angiogenic receptors45. 
Many cytokines and growth factors are involved in modulating the formation of new 
vessels. Expression of VEGF and its receptors is elevated in HCC cell lines and tissues, 
as well as in the blood circulation of patients with HCC33,46–48. In our model, nintedanib 
exerted its chemopreventive mechanisms in part through the inhibition of VEGF 
signaling, a major driver of angiogenesis49.Thus far, independent studies had described 
that HCC prevention can be achieved in animal models by attenuating liver fibrosis 
through the inhibition of epidermal growth factor receptor (EGFR)50,51 or lysophosphatidic 
acid (LPA)32 signaling. With the current study, we demonstrate that modulation of the 
liver microenvironment by molecular targeted drugs, which simultaneously block liver 
inflammation and angiogenesis, might represent a powerful alternative strategy. 
We recently defined the immune class of HCC15 and the Immune exclusion class 
(characterized by active Wnt/CTNNB1)3,15,52, which might predict response and primary 
resistance to checkpoint inhibitors, respectively3,52. We herein explore the 
immunomodulatory mechanisms underlying HCC occurrence by defining an immune-
mediated field effect that conforms a cancer-permissive milieu, thus posing them at the 
highest risk of HCC development. In addition, our pre-clinical data with a drug approved 
in pulmonology and in non-small cell lung cancer treatment suggest that the permissive 
microenvironment can be reverted leading to a reduction in HCC occurrence. These data 
provide the rationale for testing this strategy in early chemoprevention trials targeting 
cirrhotic patients at high risk of HCC development. In addition, this strategy could also 
be further explored in the adjuvant setting considering that 60% of HCC undergoing 






Figure 1. Identification of an ICF effect in non-tumoral liver tissue adjacent to early 
HCCs. A) Heatmap representation of the ICF present in 60% of HCC patients. High and 
low ssGSEA scores are represented in red and blue, respectively. B) Top predicted 
upstream cytokine and transcription factors activated in liver tissues of ICF patients. C) 
Representative images of degree of Portal/Septal infiltrating inflammation. D) 
Representative images depicting presence or absence of lymphoid aggregates.  
 
Figure 2. The ICF contains 3 distinct molecular subtypes. A) Heatmap representation 
of the three ICF subtypes. Statistical significance is highlighted. B) Immunophenogram 
representing the enrichment of immunogenic determinants in the distinct ICF subtypes 
(MHC: Antigen presenting, EC: Effector cells, CP: Check-points, SC: Suppressor Cells). 
C) Comparison of estimated proportion of immune cells (CIBERSORT method) between 
the ICF subtypes, representing those immune populations with estimated average 
fraction >5% and significant differences between the ICF subtypes. Significant statistical 
differences observed among the different ICF subtypes are highlighted (High Infiltrate, 
Purple, Immunosuppressive, Orange; Pro-inflammatory, Green; and both High Infiltrate 
and Immunosuppressive, Black). *=p<0.05, **=p<0.01 and ***=p<0.001. 
 
Figure 3. Association of the presence of the Immunnosuppressive ICF with HCC 
occurrence and prognostic variables in cirrhotic patients. (A) Kaplan-Meier 
estimates of HCC development, (B) overall survival, (C) hepatic decompensation, 
according to the presence of the Immunosuppressive ICF subtype (orange). 
 
Figure 4. Nintedanib reduces HCC onset in mice. A) Representative pictures of 
macroscopic evaluation of hepatic tumors in mice given vehicle or nintedanib sacrificed 
at 15, 17 and 18 weeks of age. Arrows indicate macroscopically visible tumors. B) 
Evaluation of overall tumor burden and HCC incidence. (#) = statistical significance for 
overall tumor burden; (*) = statistical significance for HCC incidence. C) Microscopic 
evaluation of the number of tumors per mouse in each group. D) Number of macroscopic 
tumors per mouse given vehicle or nintedanib at the different time-points. E) Diameter 
size of the largest tumor per mouse given vehicle or nintedanib at the three different time-
points. # or *=p<0.05, **=p<0.01 and ***=p<0.001. 
Figure 5. Nintedanib and Asp/Clo reduce the ICF in animal models of chronic 
inflammation and HCC development. A) Heatmap representation of high and low 
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ssGSEA scores for the 172-gene signature and gene-sets recapitulating the ICF 
subtypes. B) Representative images and quantification of CD4+ and CD8+ infiltrating 
lymphocytes in the liver of 17 weeks old mice given vehicle (n=5) or nintedanib (n=5). C) 
Western-blot analysis of VEGFR2 activation in the non-tumor liver parenchyma of 17 
weeks old mice given vehicle (n=6) or nintedanib (n=6). D) Morphometric quantification 
of blood vessel area by CD31 immunostaining in 5 randomly selected low magnification 
fields in mice given vehicle (n=5) or nintedanib (n=5). E) Single sample GSEA analysis 









Table 1. Uni- and Multivariate Analysis of risk of HCC development in cirrhotic patients 
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Hallmark Inflammatory response 
Hallmark IL6-STAT3 signaling 
TNF-α signaling via STAT1 
Hallmark TGF-β signaling 
Gene-Ontology regulation of IL2 biosynthesis 
Reactome Immune system gene-set 
Hallmark allograft rejection 
Reactome Innate immune system gene-set  
Kegg TOLL-like receptor signaling 
Reactome adaptive immune system gene-set 
Kegg Antigen processing and presentation 
Lymphocyte infiltration representative signature 
Activation of T and B cells 
Cytolytic activity 
Ectopic lymphoid structures 
Activation of monocytes/macrophages 
Immune enrichment score 
PD-1 response signature 
186-gene Poor survival signature 
Poor survival activated HSC signature 
Late recurrence HIR signature 
Liver cancer multicentric occurrence signature 
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Hallmark IL2-STAT5 signaling 
Hallmark TNF-α signaling via NF-κβ 
Stromal wound repair and angiogenesis 
Hallmark angiogenesis 
Hallmark KRAS activation 
Activated stroma 
High enrichment of HSC signature 
Hallmark epithelial-to-mesenchymal transition 
TGF-β response representative signature 
Hallmark TGF-β signaling 
Wnt/TGF-β signature 
T cells exhaustion signature 
Upregulted genes in exhausted T cells 
IFN-γ response representative signature 
Hallmark IFN-γ response 
Hallmark IFN-α response 
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Histological analysis of human samples 
Histological evaluation was performed in 98 tissue samples obtained from patients with 
early HCC included in the study cohort. The Portal/septal, pericentral and lobular 
Inflammation were assessed as follows: 0=absent; 1= mild; 2= moderate; and 3= 
marked. The presence or absence (1 or 0, respectively) of interface inflammation, as well 
as lymphoid aggregates was also evaluated. The latter structures were mainly found in 
the periportal/periseptal areas. An inflammatory infiltrate score was created by summing 
the values given by the portal/septal, lobular and interface inflammation. Pericentral 
inflammation was not considered for the scoring system since 57% of patients were 
cirrhotic. According to the final score, we defined two inflammatory categories: the 
absent-mild category if the score was < 3, and the moderate-marked category if the score 
was ³3. The presence or absence of cirrhosis was defined according to METAVIR 
algorithm1 (F0-1-2-3/F4). Ductular proliferation was also considered. Steatosis was 
assessed based on the size of the fat vesicles (macrovesicular or microvesicular) and 
the localization of the fat droplets in the liver parenchyma (periseptal/periportal, 
pericentral or lobular). The presence or absence of ballooning, apoptotic bodies and 
oncocytic change was also evaluated. Immunohistochemistry for CD4 and CD8 was 
performed in a subset of 70 patients of the training cohort. Staining was carried out on 
3μm-thick FFPE tissue sections collected from an 40-44ºC flotation bath containing 
deionized water and mounted on 25 X 75 mm positively (+) charged slides. The slides 
were dried at 60ºC in convection oven for 30min. Deparaffinization was performed 
followed by standard cell conditioning 1 (ULTRA CC1 from Ventana Medical Systems, 
Inc.). Staining was performed using Ventana BenchMark ULTRA system with the primary 
antibody approximately 20min, 36ºC. Signal was captured using ultraview universal 
diaminobenzidine (DAB) detection kit and blocked with antibody diluent (REF 251-018) 
for 8 min. Samples were counterstained with hematoxylin for 4 min and post 
counterstained with Bluing Reagent for 4 min. The primary antibodies used were anti-
CD4 (Roche, clone SP35) and anti-CD8 (Roche, clone SP57). The quantification was 
done automatically (Image J) by calculating the positive areas (μm2) -considering 5 
random areas within lobular and portal/septal infiltrates of the non-tumor liver tissue- at 
200X magnification and using the same threshold for all samples. 
 
Generation of the DEN/CCl4 animal Model 
The chemically-induced (DEN/CCl4) model was generated as previously described2,3. 
HCC was induced by a single intraperitoneal (i.p.) injection of N-diethylnitrosamine (DEN; 
Sigma-Aldrich, MO; 25 mg/kg i.p. dissolved in 0.9% sodium chloride solution) given at 
day 15 postpartum followed by 11-14 weekly injections of carbon tetrachloride (CCl4 
0.5 ml/kg i.p., dissolved in corn oil) starting at 4 weeks of age  (Supplementary Figure 
7A). Mice (n=55) were randomized at 12 weeks of age to receive 50 mg/kg/day of 
nintedanib (Boehringer Ingelheim) (n=29) or vehicle (n=26). The vehicle solution was 
formulated as follows: 1.8 % Hydroxypropyl Beta Cyclodextrin (HPß-CD), 5% acetic acid 
(10%) and Natrosol (0.5%). At 15, 17 and 18 weeks of age mice were sacrificed 48h 
after the last dose of CCl4, having been treated with nintedanib for 3, 5 and 6 weeks, 
respectively (n=15-21 per time-point). Immediately after sacrifice, livers were explanted, 
digitally photographed and weighed. The evaluation of macroscopic malignant nodules 
was assessed by two independent investigators. Based on visual criteria, a hepatic 
lesion with a diameter >0.5 mm and with dysmorphic and/or dyschromic surface was 
considered a hepatic tumor. The diameter of tumors was measured with a hand caliper. 
The biological end-points for chemopreventive efficacy were a) incidence of hepatic 
tumors, b) number of tumors and c) size, considering the largest diameter of all counted 
tumors. The largest liver lobe was fixed in buffered 4% paraformaldehyde (PFA) for 24 
hours for posterior histological and immunohistochemical analysis. In addition, samples 
of adjacent non-tumor liver were snap frozen at -80ºC for subsequent RNA and protein 
analysis. Potential treatment-related toxicity was evaluated by monitoring body weight 
losses and quantitative determination of serum aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT). 
 
Histological and Immunohistochemical analysis of the mouse samples  
Formalin-fixed paraffin-embedded (FFPE) mouse liver samples were cut in 4 μm 
sections and stained with hematoxylin and eosin (H&E) for further histological 
examination. The samples were assessed taking into consideration non-tumor and tumor 
tissue by two expert liver pathologists (CM, MS) blinded to the treatments. In the non-
tumor tissue, the number of lymphoid aggregates was determined. These were defined 
as polarized aggregates composed mainly of lymphocytes with scant plasma cells, 
neutrophils and macrophages localized in the periportal and pericentral areas with a 
measure no bigger than 0.1 mm. The presence of inflammatory infiltrates was also 
determined for the periportal, pericentral and lobular area using a scoring system as 
follows: 0=absence or rare; 1=mild; 2=mild-moderate; 3=moderate; 4=moderate-
marked; and 5=marked. Other variables such as the presence of microabscesses, 
ductular proliferation (0=absence; 1=<25% of portal tracts involved; 2=25-50% of portal 
tracts involved; 3=>50% of portal tracts involved), necrosis, steatosis, apoptotic bodies, 
were also determined. Ballooning was defined according to the following scale being 0= 
absence; 1= focal; 2= multiple foci; 3= diffuse. Hepatic fibrosis was assessed by Sirius 
Red staining. The METAVIR algorithm1 was used to grade hepatic fibrosis from F0 (no 
scarring) to F4 (cirrhosis or severe fibrosis). Also, perisinusoidal fibrosis was evaluated 
as follows 1= 0-5%; 2= 5-33%; 3= 33-66% and 4= >60%. Histologically, hepatic tumors 
presented a high cellular density composed of small cells with altered 
nuclear/cytoplasmic ratio, and a clear cytoplasm. Among these hepatic tumors, those 
circular well-defined lesions with pushing margins were diagnosed as HCCs whereas a 
dysplastic nodule was considered when the lesion had an ill-defined shape within the 
liver parenchyma. The presence of vascular invasion was a characteristic attributed to 
HCC. The size of both lesions was not used to make a distinction between them, 
although HCC tend to be larger than dysplastic nodules. Finally, for the evaluation of the 
chemopreventive effects of a TKI in adjacent liver tissue, FFPE sections from mice 
sacrificed at 17 weeks of age were analyzed by immunohistochemistry (n=5 mice per 
treatment arm). Heat-induced antigen retrieval was performed with 10 mM sodium citrate 
buffer (pH 6.0) or 0.5 M Tris buffer (pH 10.0) for 15 minutes (5 minutes, 3 times), and the 
reaction was quenched using hydrogen peroxide 3%. After washing with PBS, samples 
were incubated with anti-pERK (phosphoThr202/Tyr204) (from Cell Signaling, Danvers, 
MA), anti-CD31 (Abcam plc, Cambridge, UK), and anti-CD4 and anti-CD8 (both from Cell 
Signaling, Danvers, MA). DAB (3,3'-diaminobenzidine) was used as detection system 
(EnVision+ System-HRP, Dako). Morphometric quantification of percentage area of liver 
vasculature (n=5 mice per treatment arm) was performed by evaluating the mean area 
of CD31 staining, in randomly selected low magnification fields (n=5, 10X fields for CD31 




RNA extraction and gene expression profiling of mice livers 
Total RNA from the two mouse models herein described was extracted from 20 mg fresh-
frozen non-tumoral liver tissue with Trizol reagent (Invitrogen) and purified with RNeasy 
columns (Qiagen, Valencia, CA). RNA sample concentration and quality were assessed 
by NanoDrop ND-1000 spectrometer (NanoDrop, Wilmington, DE) and bioanalyzer 
(Agilent, Palo Alto, CA), respectively. Gene expression microarray studies were 
conducted using the Gene Chip HT MG-430 (Affymetrix). The raw .cel files were 
background corrected and normalized using the Robust Multiarray Averaging (RMA) 
procedure 4, with a custom chip definition file (.cdf) from the Custom CDF project 
(HTMG430PM_Mm_ENTREZG v18.0)5. To assess ICF-signature enrichment through 
ssGSEA (GenePattern), mice genes were humanized and intensity values were log 
transformed. For qRT-PCR analysis, cDNA was synthesized from 1 μg purified total RNA 
using SuperScript III reverse transcriptase (Invitrogen).  Relative gene expression levels 
were measured by TaqMan Gene Expression Assays (Applied Biosystems, Foster City, 
CA) using specific probes for Col1a1 (Mm00801666_g1), Col1a2 (Mm00483888_m1), 
Acta2 (Mm01546133_m1), and Pdgfrb (Mm00435546_m1). The housekeeping gene 
GAPDH (Mm99999915_g1) was used for normalization. Microarray data of these newly 
profiled samples are in GEO under accession number (GSE125975). 
 
Western-blot analysis 
Whole-cell extracts were collected in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 0.1% SDS, 0.25 mM EDTA, 1% Sodium deoxycholate) containing 
phosphatases and proteases inhibitors (Roche). 30-70 µg of total protein were resolved 
in polyacrylamide gels and transferred to nitrocellulose membranes (Pierce, Rockford, 
IL). Membranes were BSA-blocked and hybridized overnight at 4 °C with primary 
antibodies against VEGFR-2, phospho-VEGFR-2 (Tyr951), Akt, phospho-Akt (Ser473), 
ERK-1/2, phospho-ERK-1/2 (Thr202/Tyr204), Bcl-xL, PARP (all from Cell Signaling), and 
tubulin (Sigma). Appropriate HRP-conjugated secondary antibodies (Dako) were 
incubated for 1h at room temperature and immunoreactivity was detected with a LAS-
3000 imaging system (Fujifilm, Tokyo, Japan) using AmershamTM ECLTM Prime western 
Blotting Detection Reagent (GE Healthcare, United Kingdom). 
 
  
SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Figure 1. Identification of an immune-mediated cancer field in the 
non-tumor liver tissues and its association with overall survival in patients with 
early HCC. A) Consensus-clustered analysis of gene-sets recapitulating the different 
perturbation states of immune. The figure includes a subgroup of representative gene-
sets among the ~5000 gene-sets evaluated (Collection C7 of MsigDB). B) Kaplan-Meier 
estimates of overall survival according to the presence of the immune-mediated cancer 
field, B) the presence of High-Infiltrate subtype, and C) the different ICF subtypes. ICF: 
immune-mediated cancer field. C)  
 
Supplementary Figure 2. Immunohistochemistry assessment of CD4 and CD8 
positivity in non-tumor liver tissues. Average stained area was automatically 
quantified and compared in A) samples from patients belonging to the ICF and non ICF 
subgroups, and B) between ICF subtypes. n= 15-19 samples per group. ***=p<0.001. 
 
Supplementary Figure 3. Gene-overlapping between the 172 ICF gene-expression 
signature and other previously reported poor-prognosis expression signatures in 
non-tumor liver tissue. Signatures are denoted by the name of the first authors in each 
of the publications6–10. Numbers in brackets indicate the total number of genes constitute 
each signature, whereas bold numbers represent the number of genes that overlap 
between each signature and the ICF signature (herein referred as Moeini).  
 
Supplementary Figure 4. External validation of the molecular and clinical features 
of the immune-mediated cancer field and its subtypes. A) Main molecular 
characteristics of the immune-mediated cancer field and the 3 distinct molecular 
subtypes were validated in a previously reported cohort including 225 FFPE non-tumoral 
liver tissue from patients with early HCC profiled by DASL array. B) Kaplan-Meier 
estimates of overall survival according to the presence of the immune-mediated cancer 
field. ICF: immune-mediated cancer field. 
 
Supplementary Figure 5. Association of the presence of immune-mediated cancer 
field subtypes with risk of HCC development and  advanced liver disease in fibrotic 
patients. A) Kaplan-Meier analysis of the correlation of the immune-mediated cancer 
field subtypes with risk of HCC development. B) Correlation of the prediction of immune-
mediated cancer field subtypes with fibrosis and inflammation degree. Fibrosis degree 
was classified as: none (S0), low (S1-S2) and high (S3-S4). Inflammation degree was 
classified as: none (G0), low (G1-G2) and high (G3-G4). other ICF: High Infiltrate and 
Pro-inflammatory ICFs. Non ICF: non ICF subtype and unclassified cases. 
 
Supplementary Figure 6. In silico enrichment analysis of gene sets recapitulating 
the targets of approved molecular therapies in non-tumor liver of patients with 
early HCC. A) Heatmap representing the enrichment scores of gene sets recapitulating 
the molecular targets of top enriched therapies in non-tumor liver of HCC patients 
harboring the immune-mediated cancer field (ICF) in comparison to non ICF/other. B) 
Constellation map representation of enrichment of gene set of main targets of top scored 
therapies centered around the immune-mediated cancer field phenotype. The Blue lines 
denote presence of overlapping genes among the different gene sets. NMI: Normalized 
mutual information. AUC.pval: Area under the curve p-value. t.stat: t-statistic. t.pval: t-
statistic p-value. 
 
Supplementary Figure 7. Prolonged treatment with nintedanib does not induce 
significant toxicity in DEN/CCl4 induced mouse models. A) Experimental design of 
the murine model of DEN/CCl4 induced hepatocarcinogenesis in the context of liver 
fibrosis. B) Monitoring of body weight in all mice from each experimental group during 
the administration of nintedanib or vehicle at the longest time-point, 18-weeks of age. C) 
Evaluation of the serum levels of alanine transaminase (ALT) and aspartate 
transaminase (AST) in each experimental group. 
 
Supplementary Figure 8. Nintedanib inhibits downstream MAPK pathway but has 
no effect on reverting DEN/CCl4 induced PDGF signaling nor hepatic fibrosis. A) 
Western-blot analysis of downstream MAPK(AKT and ERK) signaling. B) Representative 
images and quantification of pERK staining in 17 weeks old mice treated with vehicle or 
nintedanib. In the vehicle arm the tumors and the adjacent non-tumor tissue are positive 
with patchy nuclear and cytoplasmic staining, while in the nintedanib arm both are 
negative. T: tumor. NT: non-tumor. C) Western-blot analysis of the pro-fibrogenic 
PDGFR signaling. D) Representative images of Sirius Red staining in mice treated with 
vehicle or nintedanib. Nintedanib did not exert any significant effect on liver fibrosis. E) 
Gene expression levels of pro-fibrogenic marker genes by quantitative RT-PCR in livers 
of mice sacrificed at 15, 17 and 18 weeks of age treated with vehicle or nintedanib. The 
GAPDH gene was used as a housekeeper for normalization. Significant statistical 
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High Infiltrate ICF 22 15 9 6 3 3 
Rest 142 112 86 59 29 14 
P =.006 P = ns 
High Infiltrate ICF 22 15 9 6 3 3 
Immunosuppressive ICF 35 24 18 12 9 3 
Pro-Inflammatory ICF 39 29 21 16 6 2 
ICF 96 68 48 34 18 8 
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Supplementary Figure 3 
Validation cohort  (GSE10143, n=225 non-tumor liver tissues) 





ICF 94 57 22 7 1 0 
Non ICF 90 64 25 8 4 3 
P =.003 
Supplementary Figure 4 
A 
B 
P =.06 P =.03 
Supplementary Figure 5 
Immunosuppressive ICF 21 13 3      1 
High Infiltrate ICF 31 23 13      1 
Pro-Inflammatory ICF 58 45 18      3 
Non ICF 106 87 57      10 
Immunosuppressive ICF 21 13 3 1 
Other ICF 89 68 31 3 
Non ICF 106 87 57 10 
Supplementary Figure 6 
A 
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NMI AUC.pval t.pval 
0.2484 1.30E-14 3.03E-07 
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0.2 3.16E-12 1.06E-16 
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Supplementary Figure 8 
Variable Value
Median age (years) 65.2






















BCLC early stage, 0-A (%) 82




Bilirrubin, >1 mg/dL (%) 43
Albumin, <3.5 g/L (%) 12
Platelet Count, <100.000/mm3 (%) 22




Follow-up, median months (range) 67 (53-80)
Supplementary Table 1. Clinicopathological characteristics of study cohort 
(n=167).
Missing data:  etiology (n=5), Child Pugh score (n=3, tumo size (n=2), 
multiple nodules (n=2), microvascular invasion (n=4), degree of tumor 
differentiation (n=31), bilirrubin (n=5), albumin (n=5), platelet count (n=5), AFP 
(n=5), recurrence (n=9) death (n=3), follow-up (n=3).
Supplementary Table 2. Previously reported gene signatures used in this study.
Signature Name Publication
Signatures used in non-tumor tissue
Activated stroma Moffitt RA, et al. Nat Genet 2015;47:1168-78
Activation of monocytes/macrophages Beck AH, et al. Clin Cancer Res 2009;15:778–87
Activation of T and B cells Wolf DM, et al. PLoS One 2014;9:e88309
Cholesterol-induced inflammatory response Wunder C, et al. Nat Med 2006;12:1030-8 
Cytolytic activity Rooney MS, et al. Cell 2015;160:48-61
Ectopic lymphoid structures (ELS) Finkin S, et al. Nat Immunol 2015;16(12):1235
Hepatic injury and regeneration (HIR) signature Kim JH, et al. PloS Med 2014;11:e1001770
Hepatic Stellate Cell (HSC) signature Zhang DY, et al. Gut 2016;65:1754-64
Immune enrichment score Yoshihara K, et al. Nat Commun 2013;4:2612
Liver cancer multicentric occurrence Okamoto M, et al Ann Surg Oncol 2006;13:947-54 
Lymphocyte infiltration representative signature Thorsson V, et al. Immunity 2018;48:812-30
PD-1 response signature Quigley M, et al. Nat Med 2010;16:1147-51
Poor survival activated HSC signature Ji J, et al. Hepatology 2015;62:481-95
Stromal enrichment score Yoshihara K, et al. Nat Commun 2013;4:2612
Stromal wound repair and angiogenesis Wolf DM, et al. PLoS One 2014;9:e88309
T cell exhaustion signature Quigley M, et al. Nat Med 2010;16:1147-51
TGF-β response representative signature Thorsson V, et al. Immunity 2018;48:812-30
Upregulated genes in exhausted T cells Wherry EJ, et al. Immunity 2007;27:670–684
Wnt/TGF-β signature Lachenmayer A, et al. Clin Cancer Res 2012;18:4997-5007 
18-gene IFN-γ-related signature Ayers M, et al. J Clin Invest 2017; 127:2930–40 
186-gene Poor survival signature Hoshida Y, et al. N Engl J Med 2008;359:1995-2004
Signatures of HCC molecular subclasses 
Boyault G3 class Boyault S, et al. Hepatology 2007;45:42-52
Chiang HCC 5 classes Chiang DY, et al. Cancer Res 2008;68:6779-88
Coulouarn late vs early TGF-β Coulouarn C, et al. Hepatology. 2008;47:2059-67
Hoshida S1-S2-S3 Hoshida Y, et al. Cancer Res 2009;69:7385-92
Lee Cluster A Lee JS, et al. Hepatology 2004;40:667–76
Minguez vascular invasion Minguez B, et al. J Hepatol. 2011;55:1325-31
Sia HCC Immune class Sia D, et al. Gastroenterology 2017;153:812-26 
Villanueva CK19 positive Villanueva A, et al. Gastroenterology 2011;140:1501-12.e2
Villanueva NOTCH Villanueva A, et al. Gastroenterology 2012;143:1660-1669.e7
Woo early recurrence Woo HG, et al. Clin Cancer Res 2008;14:2056–64
Yamashita EpCAM Yamashita T, et al. Cancer Res 2008;68:1451–61
Fisher test
% n patients % n patients p-value
Non-tumor tissue characteristics
Fibrosis degree and cirrhosis
F1-F2 11% (7/71) 29% (17/59) 0.01
F3 17% (12/71) 22% (13/59) 0.37
F4 (cirrhosis) 75% (9/71) 49% (29/59) 0.002
Portal/Septal Inflammation
Absent-mild 26% (14/54) 50% (22/44)
Moderate-Marked 74% (40/54) 50% (22/44) 0.02
Lobular Inflammation
Absent-mild 94% (51/54) 98% (43/44)
Moderate-Marked 6% (3/54) 2% (1/44) 0.63
Interface Inflammation
Present 37% (20/54) 23% (10/44)
Absent 63% (34/54) 77% (34/44) 0.19
Non-tumoral Inflammatory infiltrate score
Absent-Mild 26% (14/54) 48% (21/44)
Moderate-Marked 74% (40/54) 52% (23/44) 0.03
Non-Tumoral lymphoid aggregates
Absent 20% (11/54) 45% (20/44)
Present 80% (43/54) 55% (24/44) 0.01
Apoptotic bodies
Absent 83% (45/54) 77% (34/44) 0.61
Present 17% (9/54) 23% (10/44)
Tumor tissue characteristics
Number of lesions
Single 63% (62/98) 78% (54/69)
Multinodular 35% (34/98) 22% (15/69) 0.08
Tumor size
>3.5cm 58% (56/97) 45% (31/69)
<3.5cm 42% (41/97) 54% (37/69) 0.15
Tumor satellites
Yes 34% (33/97) 25% (17/69) 0.23
No 66% (64/97) 75% (52/69)
Microscopic vascular invasion
Yes 42% (41/98) 30% (21/69) 0.19
No 56% (55/98) 67% (46/69)
Histological grade
Well 15% (15/98) 10% (7/69) 0.63
Moderate 48% (47/98) 46% (32/69) 0.59
Poor 22% (22/98) 19% (13/69) 1.00
Intratumoral inflammatory infiltrate
Mild 19% (10/54) 21% (9/42) 0.80
Moderate 41% (22/54) 55% (23/42) 0.30
Marked 37% (20/54) 24% (10/42) 0.18
Intratumoral Neutrophilic infiltrate
Absent-rare 78% (42/54) 64% (27/42)
Present 22% (12/54) 36% (15/42) 0.17
Peritumoral inflammatory infiltrate
Mild 37% (20/54) 24% (10/42) 0.18
Moderate 41% (22/54) 55% (23/42) 0.30
Marked 19% (10/54) 21% (9/42) 0.80
Tertiary Lymphoid Structures (TLS)
Present 22% (12/54) 8% (8/42)
Absent 77% (42/54) 35% (34/42) 0.80
ICF non ICF
Supplementary Table 3. Correlation of the immune-mediated cancer field (ICF) with histological 
characteristics.
Variable
NAME MSigDB collection SIZE ES NES
HALLMARK_ALLOGRAFT_REJECTION Hallmark 198 0.69 1.98
HALLMARK_IL2_STAT5_SIGNALING Hallmark 196 0.56 1.86
HALLMARK_INFLAMMATORY_RESPONSE Hallmark 200 0.61 1.85
HALLMARK_COMPLEMENT Hallmark 200 0.53 1.80
HALLMARK_KRAS_SIGNALING_UP Hallmark 199 0.53 1.80
HALLMARK_INTERFERON_GAMMA_RESPONSE Hallmark 200 0.70 1.78
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION Hallmark 199 0.64 1.77
HALLMARK_TGF_BETA_SIGNALING Hallmark 54 0.61 1.74
HALLMARK_IL6_JAK_STAT3_SIGNALING Hallmark 87 0.61 1.73
HALLMARK_ANGIOGENESIS Hallmark 36 0.67 1.73
HALLMARK_APOPTOSIS Hallmark 160 0.50 1.68
HALLMARK_TNFA_SIGNALING_VIA_NFKB Hallmark 198 0.64 1.65
JAATINEN_HEMATOPOIETIC_STEM_CELL_DN C2 220 0.64 1.96
REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL C2 60 0.69 1.96
KHETCHOUMIAN_TRIM24_TARGETS_UP C2 45 0.79 1.96
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_DN C2 182 0.57 1.96
CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP C2 173 0.67 1.96
KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS C2 91 0.59 1.96
PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_DN C2 164 0.62 1.95
BASSO_CD40_SIGNALING_UP C2 99 0.72 1.95
LINDGREN_BLADDER_CANCER_CLUSTER_2B C2 375 0.67 1.95
FINAK_BREAST_CANCER_SDPP_SIGNATURE C2 24 0.82 1.94
MCLACHLAN_DENTAL_CARIES_UP C2 236 0.72 1.94
FIGUEROA_AML_METHYLATION_CLUSTER_5_DN C2 42 0.54 1.94
LI_INDUCED_T_TO_NATURAL_KILLER_UP C2 297 0.55 1.93
KEGG_VIRAL_MYOCARDITIS C2 68 0.64 1.93
HENDRICKS_SMARCA4_TARGETS_DN C2 48 0.62 1.93
KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION C2 51 0.70 1.93
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION C2 113 0.57 1.93
BOYLAN_MULTIPLE_MYELOMA_C_D_DN C2 246 0.54 1.92
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP C2 87 0.81 1.92
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_35D_UP C2 128 0.72 1.92
PASINI_SUZ12_TARGETS_DN C2 312 0.62 1.92
DUNNE_TARGETS_OF_AML1_MTG8_FUSION_UP C2 50 0.66 1.92
AMUNDSON_POOR_SURVIVAL_AFTER_GAMMA_RADIATION_2G C2 168 0.56 1.92
BOYLAN_MULTIPLE_MYELOMA_D_DN C2 75 0.62 1.92
FAELT_B_CLL_WITH_VH_REARRANGEMENTS_UP C2 46 0.60 1.91
WALLACE_PROSTATE_CANCER_RACE_UP C2 281 0.70 1.91
HOSHIDA_LIVER_CANCER_SURVIVAL_UP C2 73 0.72 1.91
HUANG_GATA2_TARGETS_UP C2 147 0.60 1.91
DIAZ_CHRONIC_MEYLOGENOUS_LEUKEMIA_DN C2 115 0.64 1.91
MARSON_FOXP3_TARGETS_UP C2 65 0.68 1.91
HUANG_DASATINIB_RESISTANCE_UP C2 78 0.69 1.90
HOFMANN_MYELODYSPLASTIC_SYNDROM_RISK_DN C2 22 0.66 1.90
SU_THYMUS C2 20 0.79 1.90
GAURNIER_PSMD4_TARGETS C2 70 0.68 1.90
KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION C2 45 0.69 1.90
SCHUETZ_BREAST_CANCER_DUCTAL_INVASIVE_UP C2 345 0.73 1.90
AMUNDSON_POOR_SURVIVAL_AFTER_GAMMA_RADIATION_8G C2 93 0.57 1.90
VERHAAK_AML_WITH_NPM1_MUTATED_DN C2 240 0.57 1.90
REACTOME_HEMOSTASIS C2 442 0.46 1.90
JOHANSSON_GLIOMAGENESIS_BY_PDGFB_UP C2 56 0.66 1.89
GRUETZMANN_PANCREATIC_CANCER_UP C2 352 0.61 1.89
NAKAYAMA_SOFT_TISSUE_TUMORS_PCA1_UP C2 73 0.75 1.89
VALK_AML_CLUSTER_11 C2 36 0.61 1.89
WU_CELL_MIGRATION C2 180 0.61 1.89
HADDAD_T_LYMPHOCYTE_AND_NK_PROGENITOR_DN C2 62 0.64 1.89
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION C2 77 0.64 1.89
PID_IL12_2PATHWAY C2 62 0.65 1.89
PID_CXCR4_PATHWAY C2 102 0.60 1.88
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_UP C2 167 0.54 1.88
ONO_FOXP3_TARGETS_DN C2 42 0.68 1.88
REACTOME_INFLAMMASOMES C2 16 0.76 1.88
RUTELLA_RESPONSE_TO_HGF_VS_CSF2RB_AND_IL4_DN C2 240 0.55 1.88
PID_GLYPICAN_1PATHWAY C2 26 0.74 1.88
RUTELLA_RESPONSE_TO_HGF_DN C2 229 0.57 1.88
KIM_GLIS2_TARGETS_UP C2 84 0.74 1.88
ONO_AML1_TARGETS_DN C2 41 0.64 1.88
REACTOME_INTERFERON_SIGNALING C2 151 0.63 1.88
YU_MYC_TARGETS_DN C2 53 0.68 1.87
WANG_ESOPHAGUS_CANCER_VS_NORMAL_UP C2 117 0.58 1.87
CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_DN C2 451 0.63 1.87
LINDSTEDT_DENDRITIC_CELL_MATURATION_D C2 67 0.64 1.87
LU_IL4_SIGNALING C2 89 0.61 1.87
OSADA_ASCL1_TARGETS_DN C2 24 0.75 1.87
KEGG_CELL_ADHESION_MOLECULES_CAMS C2 130 0.53 1.87
DER_IFN_GAMMA_RESPONSE_UP C2 71 0.72 1.87
HELLER_SILENCED_BY_METHYLATION_UP C2 269 0.52 1.87
REACTOME_PLATELET_ACTIVATION_SIGNALING_AND_AGGREGATION C2 196 0.53 1.87
REACTOME_SEMAPHORIN_INTERACTIONS C2 63 0.64 1.87
LIU_VAV3_PROSTATE_CARCINOGENESIS_UP C2 88 0.63 1.87
PID_IL12_STAT4_PATHWAY C2 33 0.71 1.87
LIANG_SILENCED_BY_METHYLATION_UP C2 30 0.65 1.87
WIERENGA_STAT5A_TARGETS_DN C2 202 0.52 1.87
DEMAGALHAES_AGING_UP C2 53 0.68 1.86
ZHAN_EARLY_DIFFERENTIATION_GENES_DN C2 42 0.63 1.86
SWEET_KRAS_TARGETS_UP C2 82 0.63 1.86
GNATENKO_PLATELET_SIGNATURE C2 45 0.71 1.86
SERVITJA_ISLET_HNF1A_TARGETS_UP C2 162 0.56 1.86
RASHI_RESPONSE_TO_IONIZING_RADIATION_6 C2 81 0.59 1.86
RAGHAVACHARI_PLATELET_SPECIFIC_GENES C2 70 0.66 1.86
JACKSON_DNMT1_TARGETS_UP C2 77 0.63 1.86
BOSCO_TH1_CYTOTOXIC_MODULE C2 112 0.57 1.86
CHEOK_RESPONSE_TO_HD_MTX_UP C2 22 0.76 1.86
DER_IFN_BETA_RESPONSE_UP C2 102 0.71 1.86
KEGG_CHEMOKINE_SIGNALING_PATHWAY C2 179 0.55 1.86
Supplementary Table 4. Pathways enriched by GSEA in immune-mediated cancer field.
IGLESIAS_E2F_TARGETS_UP C2 149 0.66 1.86
DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_UP C2 253 0.54 1.86
KEGG_ASTHMA C2 28 0.69 1.86
REACTOME_INTEGRIN_CELL_SURFACE_INTERACTIONS C2 79 0.63 1.86
MUNSHI_MULTIPLE_MYELOMA_UP C2 81 0.57 1.86
REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING C2 28 0.68 1.86
CROONQUIST_NRAS_SIGNALING_UP C2 39 0.72 1.86
MORI_SMALL_PRE_BII_LYMPHOCYTE_UP C2 85 0.55 1.85
PID_CD8_TCR_PATHWAY C2 52 0.69 1.85
ICHIBA_GRAFT_VERSUS_HOST_DISEASE_D7_UP C2 107 0.72 1.85
KEGG_LEISHMANIA_INFECTION C2 68 0.67 1.85
YAN_ESCAPE_FROM_ANOIKIS C2 24 0.74 1.85
PID_RAC1_PATHWAY C2 51 0.58 1.85
REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM C2 260 0.56 1.85
BORLAK_LIVER_CANCER_EGF_UP C2 55 0.65 1.85
REACTOME_TCR_SIGNALING C2 49 0.69 1.85
BASSO_HAIRY_CELL_LEUKEMIA_UP C2 80 0.63 1.85
SCHRAETS_MLL_TARGETS_DN C2 33 0.66 1.85
GOLDRATH_ANTIGEN_RESPONSE C2 337 0.54 1.85
WIELAND_UP_BY_HBV_INFECTION C2 98 0.80 1.85
REACTOME_GPVI_MEDIATED_ACTIVATION_CASCADE C2 30 0.73 1.85
LINDSTEDT_DENDRITIC_CELL_MATURATION_C C2 68 0.60 1.85
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_HSC_UP C2 180 0.57 1.85
GUENTHER_GROWTH_SPHERICAL_VS_ADHERENT_DN C2 25 0.71 1.84
PID_TCR_PATHWAY C2 65 0.66 1.84
SASSON_RESPONSE_TO_FORSKOLIN_DN C2 87 0.62 1.84
KEGG_SMALL_CELL_LUNG_CANCER C2 84 0.54 1.84
CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN C2 441 0.57 1.84
RADMACHER_AML_PROGNOSIS C2 77 0.60 1.84
REN_ALVEOLAR_RHABDOMYOSARCOMA_DN C2 406 0.61 1.84
KEGG_AUTOIMMUNE_THYROID_DISEASE C2 48 0.61 1.84
LEE_DIFFERENTIATING_T_LYMPHOCYTE C2 187 0.68 1.84
HELLER_HDAC_TARGETS_DN C2 284 0.51 1.84
LEE_LIVER_CANCER_DENA_UP C2 59 0.67 1.84
DIRMEIER_LMP1_RESPONSE_LATE_UP C2 56 0.70 1.84
PID_ILK_PATHWAY C2 45 0.65 1.84
CHAUHAN_RESPONSE_TO_METHOXYESTRADIOL_DN C2 100 0.64 1.84
HELLEBREKERS_SILENCED_DURING_TUMOR_ANGIOGENESIS C2 80 0.59 1.84
DER_IFN_ALPHA_RESPONSE_UP C2 74 0.74 1.84
WOO_LIVER_CANCER_RECURRENCE_UP C2 105 0.77 1.84
PETROVA_PROX1_TARGETS_DN C2 64 0.72 1.84
PID_PI3KCI_PATHWAY C2 48 0.63 1.84
MA_MYELOID_DIFFERENTIATION_UP C2 39 0.65 1.84
VANASSE_BCL2_TARGETS_DN C2 72 0.51 1.84
BARIS_THYROID_CANCER_DN C2 58 0.59 1.84
HE_PTEN_TARGETS_UP C2 16 0.74 1.84
MORI_LARGE_PRE_BII_LYMPHOCYTE_DN C2 57 0.71 1.84
ROSS_ACUTE_MYELOID_LEUKEMIA_CBF C2 79 0.55 1.84
ROSS_AML_WITH_CBFB_MYH11_FUSION C2 50 0.66 1.84
PID_NFAT_3PATHWAY C2 53 0.60 1.83
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY C2 127 0.51 1.83
SASSON_RESPONSE_TO_GONADOTROPHINS_DN C2 87 0.62 1.83
FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_UP C2 85 0.56 1.83
PANGAS_TUMOR_SUPPRESSION_BY_SMAD1_AND_SMAD5_UP C2 132 0.54 1.83
RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_UP C2 30 0.64 1.83
GEORGANTAS_HSC_MARKERS C2 66 0.60 1.83
SHIN_B_CELL_LYMPHOMA_CLUSTER_2 C2 30 0.63 1.83
RAY_TARGETS_OF_P210_BCR_ABL_FUSION_DN C2 15 0.79 1.83
PID_PDGFRB_PATHWAY C2 126 0.56 1.83
WIKMAN_ASBESTOS_LUNG_CANCER_DN C2 28 0.67 1.83
RODWELL_AGING_KIDNEY_NO_BLOOD_UP C2 211 0.62 1.83
JI_CARCINOGENESIS_BY_KRAS_AND_STK11_DN C2 17 0.77 1.82
GRAHAM_CML_DIVIDING_VS_NORMAL_QUIESCENT_DN C2 90 0.65 1.82
PHONG_TNF_RESPONSE_NOT_VIA_P38 C2 337 0.51 1.82
THUM_SYSTOLIC_HEART_FAILURE_UP C2 405 0.58 1.82
DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN C2 307 0.61 1.82
XU_RESPONSE_TO_TRETINOIN_AND_NSC682994_UP C2 17 0.79 1.82
VALK_AML_CLUSTER_4 C2 28 0.69 1.82
REACTOME_INTERFERON_GAMMA_SIGNALING C2 59 0.68 1.82
FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP C2 61 0.65 1.82
BYSTROEM_CORRELATED_WITH_IL5_UP C2 49 0.59 1.82
NIELSEN_LEIOMYOSARCOMA_CNN1_DN C2 20 0.77 1.82
GILDEA_METASTASIS C2 30 0.77 1.82
CROONQUIST_IL6_DEPRIVATION_UP C2 20 0.69 1.82
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_CDC25_UP C2 57 0.63 1.81
LE_SKI_TARGETS_UP C2 17 0.76 1.81
SNIJDERS_AMPLIFIED_IN_HEAD_AND_NECK_TUMORS C2 37 0.66 1.81
LEE_EARLY_T_LYMPHOCYTE_DN C2 54 0.74 1.81
BOSCO_ALLERGEN_INDUCED_TH2_ASSOCIATED_MODULE C2 141 0.57 1.81
PID_FCER1_PATHWAY C2 60 0.65 1.81
BIOCARTA_MEF2D_PATHWAY C2 18 0.72 1.81
ISSAEVA_MLL2_TARGETS C2 59 0.59 1.81
HAN_JNK_SINGALING_UP C2 35 0.68 1.81
OSMAN_BLADDER_CANCER_DN C2 376 0.55 1.81
REACTOME_DOWNSTREAM_TCR_SIGNALING C2 33 0.66 1.81
FRIDMAN_SENESCENCE_UP C2 76 0.60 1.81
REACTOME_CHEMOKINE_RECEPTORS_BIND_CHEMOKINES C2 51 0.63 1.81
LEE_LIVER_CANCER_SURVIVAL_DN C2 170 0.71 1.81
SMIRNOV_RESPONSE_TO_IR_6HR_DN C2 111 0.56 1.81
MORI_MATURE_B_LYMPHOCYTE_UP C2 89 0.62 1.81
BURTON_ADIPOGENESIS_8 C2 85 0.65 1.81
WU_HBX_TARGETS_2_DN C2 16 0.77 1.81
YAGI_AML_WITH_T_8_21_TRANSLOCATION C2 362 0.47 1.81
NAKAMURA_METASTASIS C2 46 0.63 1.81
SHIN_B_CELL_LYMPHOMA_CLUSTER_8 C2 36 0.63 1.81
BIOCARTA_TH1TH2_PATHWAY C2 19 0.72 1.81
STEIN_ESRRA_TARGETS_DN C2 102 0.58 1.81
LEE_LIVER_CANCER_MYC_E2F1_UP C2 55 0.62 1.81
MORI_IMMATURE_B_LYMPHOCYTE_UP C2 52 0.71 1.81
DANG_REGULATED_BY_MYC_DN C2 250 0.51 1.81
TING_SILENCED_BY_DICER C2 30 0.63 1.81
BURTON_ADIPOGENESIS_9 C2 90 0.61 1.81
ZHU_CMV_ALL_UP C2 119 0.61 1.81
HUMMERICH_SKIN_CANCER_PROGRESSION_UP C2 86 0.60 1.81
ZHAN_MULTIPLE_MYELOMA_HP_UP C2 46 0.61 1.81
IZADPANAH_STEM_CELL_ADIPOSE_VS_BONE_UP C2 124 0.58 1.81
LINDSTEDT_DENDRITIC_CELL_MATURATION_B C2 51 0.72 1.81
HAHTOLA_CTCL_PATHOGENESIS C2 15 0.83 1.80
VERRECCHIA_EARLY_RESPONSE_TO_TGFB1 C2 55 0.65 1.80
LENAOUR_DENDRITIC_CELL_MATURATION_UP C2 112 0.53 1.80
TARTE_PLASMA_CELL_VS_B_LYMPHOCYTE_DN C2 37 0.74 1.80
ONO_FOXP3_TARGETS_UP C2 23 0.69 1.80
REACTOME_NUCLEOTIDE_BINDING_DOMAIN_LEUCINE_RICH_REPEAT_CONTAINING_RECEPTOR_NLR_SIGNALING_PATHWAYSC2 44 0.60 1.80
ALONSO_METASTASIS_EMT_UP C2 36 0.67 1.80
REACTOME_PHOSPHORYLATION_OF_CD3_AND_TCR_ZETA_CHAINS C2 15 0.85 1.80
DELYS_THYROID_CANCER_UP C2 434 0.52 1.80
PETROVA_ENDOTHELIUM_LYMPHATIC_VS_BLOOD_DN C2 162 0.61 1.80
VANTVEER_BREAST_CANCER_ESR1_DN C2 234 0.53 1.80
REACTOME_METABOLISM_OF_MRNA C2 206 0.65 1.80
SYED_ESTRADIOL_RESPONSE C2 18 0.72 1.80
BOYAULT_LIVER_CANCER_SUBCLASS_G5_DN C2 27 0.82 1.80
ZHANG_PROLIFERATING_VS_QUIESCENT C2 49 0.62 1.80
PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP C2 204 0.63 1.80
KUNINGER_IGF1_VS_PDGFB_TARGETS_DN C2 45 0.59 1.80
HELLER_HDAC_TARGETS_SILENCED_BY_METHYLATION_DN C2 272 0.50 1.80
GRANDVAUX_IRF3_TARGETS_DN C2 19 0.67 1.80
MARKEY_RB1_ACUTE_LOF_DN C2 222 0.57 1.80
VALK_AML_CLUSTER_15 C2 30 0.59 1.80
PID_CD40_PATHWAY C2 31 0.63 1.80
NEMETH_INFLAMMATORY_RESPONSE_LPS_UP C2 88 0.64 1.80
BIOCARTA_P38MAPK_PATHWAY C2 39 0.60 1.80
BIOCARTA_IL17_PATHWAY C2 15 0.72 1.80
GU_PDEF_TARGETS_UP C2 71 0.61 1.80
PID_SYNDECAN_2_PATHWAY C2 33 0.65 1.80
JIANG_TIP30_TARGETS_UP C2 45 0.62 1.80
NUTT_GBM_VS_AO_GLIOMA_UP C2 46 0.63 1.80
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP C2 155 0.54 1.80
HESS_TARGETS_OF_HOXA9_AND_MEIS1_DN C2 76 0.63 1.79
WINTER_HYPOXIA_DN C2 49 0.75 1.79
NAKAMURA_METASTASIS_MODEL_UP C2 43 0.60 1.79
WUNDER_INFLAMMATORY_RESPONSE_AND_CHOLESTEROL_UP C2 55 0.65 1.79
LEE_AGING_CEREBELLUM_UP C2 83 0.54 1.79
MORI_PLASMA_CELL_DN C2 32 0.69 1.79
REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL C2 84 0.53 1.79
HAHTOLA_MYCOSIS_FUNGOIDES_SKIN_UP C2 176 0.62 1.79
POMEROY_MEDULLOBLASTOMA_DESMOPLASIC_VS_CLASSIC_DN C2 59 0.64 1.79
BRUECKNER_TARGETS_OF_MIRLET7A3_DN C2 76 0.60 1.79
REACTOME_METABOLISM_OF_RNA C2 250 0.65 1.79
BIOCARTA_MCALPAIN_PATHWAY C2 25 0.61 1.79
KEGG_VASOPRESSIN_REGULATED_WATER_REABSORPTION C2 44 0.58 1.79
DELPUECH_FOXO3_TARGETS_UP C2 68 0.57 1.79
GAZDA_DIAMOND_BLACKFAN_ANEMIA_PROGENITOR_UP C2 38 0.65 1.79
BOQUEST_STEM_CELL_DN C2 215 0.57 1.79
SHIN_B_CELL_LYMPHOMA_CLUSTER_3 C2 27 0.71 1.79
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_2_DN C2 51 0.64 1.79
WORSCHECH_TUMOR_REJECTION_UP C2 54 0.61 1.79
WATTEL_AUTONOMOUS_THYROID_ADENOMA_DN C2 55 0.63 1.79
BIOCARTA_RHO_PATHWAY C2 31 0.62 1.79
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM2 C2 151 0.50 1.79
KEGG_CHRONIC_MYELOID_LEUKEMIA C2 72 0.52 1.79
LEE_NEURAL_CREST_STEM_CELL_UP C2 146 0.48 1.79
VILIMAS_NOTCH1_TARGETS_UP C2 50 0.68 1.78
MORI_PRE_BI_LYMPHOCYTE_DN C2 75 0.59 1.78
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_MONOCYTE_DN C2 54 0.65 1.78
REACTOME_AXON_GUIDANCE C2 239 0.48 1.78
KEEN_RESPONSE_TO_ROSIGLITAZONE_DN C2 104 0.64 1.78
KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY C2 62 0.59 1.78
MA_PITUITARY_FETAL_VS_ADULT_DN C2 19 0.71 1.78
PID_AVB3_OPN_PATHWAY C2 31 0.69 1.78
KANG_AR_TARGETS_UP C2 17 0.73 1.78
BIOCARTA_TCR_PATHWAY C2 43 0.65 1.78
KAPOSI_LIVER_CANCER_MET_UP C2 17 0.75 1.78
DAVIES_MULTIPLE_MYELOMA_VS_MGUS_DN C2 27 0.76 1.78
HSIAO_HOUSEKEEPING_GENES C2 384 0.66 1.78
TORCHIA_TARGETS_OF_EWSR1_FLI1_FUSION_DN C2 309 0.47 1.78
PID_CD8_TCR_DOWNSTREAM_PATHWAY C2 64 0.55 1.78
AKL_HTLV1_INFECTION_DN C2 65 0.60 1.77
DORSEY_GAB2_TARGETS C2 31 0.66 1.77
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_1_UP C2 34 0.61 1.77
KEGG_HEMATOPOIETIC_CELL_LINEAGE C2 85 0.52 1.77
GERHOLD_ADIPOGENESIS_DN C2 63 0.68 1.77
MORI_SMALL_PRE_BII_LYMPHOCYTE_DN C2 74 0.57 1.77
WATANABE_RECTAL_CANCER_RADIOTHERAPY_RESPONSIVE_DN C2 91 0.61 1.77
ZHENG_BOUND_BY_FOXP3 C2 479 0.54 1.77
BURTON_ADIPOGENESIS_7 C2 50 0.63 1.77
TOMLINS_PROSTATE_CANCER_DN C2 40 0.67 1.77
KEGG_FOCAL_ADHESION C2 196 0.54 1.77
HERNANDEZ_MITOTIC_ARREST_BY_DOCETAXEL_2_UP C2 60 0.51 1.77
WIERENGA_STAT5A_TARGETS_GROUP2 C2 56 0.60 1.77
RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_UP C2 332 0.50 1.77
LIM_MAMMARY_LUMINAL_MATURE_DN C2 97 0.60 1.77
BILANGES_SERUM_RESPONSE_TRANSLATION C2 36 0.69 1.77
CHIARETTI_T_ALL_REFRACTORY_TO_THERAPY C2 28 0.61 1.77
LIU_SMARCA4_TARGETS C2 59 0.56 1.77
JISON_SICKLE_CELL_DISEASE_DN C2 174 0.60 1.77
BASSO_CD40_SIGNALING_DN C2 66 0.54 1.77
BIOCARTA_FCER1_PATHWAY C2 38 0.64 1.77
BERTUCCI_MEDULLARY_VS_DUCTAL_BREAST_CANCER_UP C2 200 0.54 1.77
MATSUDA_NATURAL_KILLER_DIFFERENTIATION C2 471 0.44 1.77
BIOCARTA_IL2RB_PATHWAY C2 38 0.62 1.77
REACTOME_SIGNALING_BY_ILS C2 105 0.56 1.77
PID_BCR_5PATHWAY C2 65 0.60 1.77
RASHI_RESPONSE_TO_IONIZING_RADIATION_2 C2 126 0.58 1.76
BOYAULT_LIVER_CANCER_SUBCLASS_G3_UP C2 185 0.65 1.76
WIEDERSCHAIN_TARGETS_OF_BMI1_AND_PCGF2 C2 57 0.62 1.76
KYNG_RESPONSE_TO_H2O2 C2 69 0.60 1.76
ST_INTEGRIN_SIGNALING_PATHWAY C2 81 0.54 1.76
ZUCCHI_METASTASIS_DN C2 44 0.70 1.76
REACTOME_COSTIMULATION_BY_THE_CD28_FAMILY C2 61 0.56 1.76
WESTON_VEGFA_TARGETS C2 106 0.56 1.76
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_UP C2 125 0.56 1.76
ALONSO_METASTASIS_NEURAL_UP C2 17 0.71 1.76
FLECHNER_PBL_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP C2 151 0.53 1.76
HORIUCHI_WTAP_TARGETS_UP C2 290 0.51 1.76
LENAOUR_DENDRITIC_CELL_MATURATION_DN C2 127 0.58 1.76
CHYLA_CBFA2T3_TARGETS_UP C2 374 0.43 1.76
SANA_TNF_SIGNALING_DN C2 88 0.62 1.76
CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_UP C2 170 0.51 1.76
PID_EPHA_FWDPATHWAY C2 34 0.58 1.76
CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_CDC25_DN C2 50 0.65 1.76
ALCALA_APOPTOSIS C2 86 0.62 1.76
ZHOU_TNF_SIGNALING_4HR C2 54 0.65 1.76
RUTELLA_RESPONSE_TO_CSF2RB_AND_IL4_DN C2 309 0.53 1.76
LINDVALL_IMMORTALIZED_BY_TERT_UP C2 74 0.58 1.76
PID_TXA2PATHWAY C2 57 0.59 1.76
MISSIAGLIA_REGULATED_BY_METHYLATION_UP C2 118 0.58 1.76
REACTOME_INFLUENZA_LIFE_CYCLE C2 134 0.71 1.76
CAIRO_HEPATOBLASTOMA_UP C2 202 0.57 1.75
PARK_HSC_AND_MULTIPOTENT_PROGENITORS C2 48 0.59 1.75
DOANE_RESPONSE_TO_ANDROGEN_DN C2 230 0.45 1.75
KEGG_ALLOGRAFT_REJECTION C2 35 0.71 1.75
ROZANOV_MMP14_TARGETS_SUBSET C2 33 0.69 1.75
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY C2 107 0.52 1.75
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP C2 70 0.62 1.75
SWEET_LUNG_CANCER_KRAS_DN C2 426 0.50 1.75
RHEIN_ALL_GLUCOCORTICOID_THERAPY_UP C2 74 0.66 1.75
PID_INTEGRIN_A4B1_PATHWAY C2 33 0.65 1.75
HINATA_NFKB_TARGETS_KERATINOCYTE_UP C2 91 0.62 1.75
TIEN_INTESTINE_PROBIOTICS_6HR_UP C2 55 0.69 1.75
KLEIN_PRIMARY_EFFUSION_LYMPHOMA_DN C2 58 0.68 1.75
HOELZEL_NF1_TARGETS_UP C2 130 0.50 1.75
TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_GRANULOCYTE_DN C2 15 0.78 1.75
GOLUB_ALL_VS_AML_UP C2 24 0.68 1.75
APRELIKOVA_BRCA1_TARGETS C2 47 0.65 1.75
SHIPP_DLBCL_VS_FOLLICULAR_LYMPHOMA_DN C2 45 0.66 1.75
BIOCARTA_CTLA4_PATHWAY C2 19 0.73 1.75
REACTOME_GENERATION_OF_SECOND_MESSENGER_MOLECULES C2 25 0.76 1.75
HASLINGER_B_CLL_WITH_CHROMOSOME_12_TRISOMY C2 24 0.66 1.75
SANA_TNF_SIGNALING_UP C2 82 0.61 1.75
FOSTER_TOLERANT_MACROPHAGE_DN C2 403 0.53 1.75
BENPORATH_ES_CORE_NINE_CORRELATED C2 100 0.53 1.75
KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INFECTION C2 68 0.53 1.75
XU_RESPONSE_TO_TRETINOIN_UP C2 15 0.69 1.75
THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN C2 225 0.53 1.75
ZHAN_MULTIPLE_MYELOMA_DN C2 40 0.61 1.75
MARKEY_RB1_CHRONIC_LOF_DN C2 117 0.53 1.75
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP C2 185 0.52 1.75
GHO_ATF5_TARGETS_DN C2 16 0.69 1.75
LIAN_NEUTROPHIL_GRANULE_CONSTITUENTS C2 25 0.66 1.74
BROWNE_HCMV_INFECTION_8HR_DN C2 45 0.58 1.74
KLEIN_TARGETS_OF_BCR_ABL1_FUSION C2 45 0.65 1.74
YAGI_AML_FAB_MARKERS C2 187 0.49 1.74
CHIBA_RESPONSE_TO_TSA_UP C2 51 0.64 1.74
FUJII_YBX1_TARGETS_UP C2 41 0.57 1.74
BROCKE_APOPTOSIS_REVERSED_BY_IL6 C2 141 0.61 1.74
ZHANG_RESPONSE_TO_IKK_INHIBITOR_AND_TNF_UP C2 217 0.56 1.74
NADLER_OBESITY_UP C2 59 0.73 1.74
BOYLAN_MULTIPLE_MYELOMA_D_CLUSTER_DN C2 40 0.55 1.74
SIG_REGULATION_OF_THE_ACTIN_CYTOSKELETON_BY_RHO_GTPASES C2 35 0.57 1.74
YAMASHITA_LIVER_CANCER_WITH_EPCAM_UP C2 51 0.63 1.74
ROSS_LEUKEMIA_WITH_MLL_FUSIONS C2 76 0.55 1.74
ZHAN_MULTIPLE_MYELOMA_LB_DN C2 39 0.68 1.74
WILENSKY_RESPONSE_TO_DARAPLADIB C2 28 0.75 1.74
MARSON_FOXP3_CORE_DIRECT_TARGETS C2 19 0.78 1.74
KANG_GIST_WITH_PDGFRA_UP C2 50 0.53 1.74
LIU_TARGETS_OF_VMYB_VS_CMYB_DN C2 40 0.68 1.74
PLASARI_TGFB1_SIGNALING_VIA_NFIC_1HR_UP C2 33 0.63 1.73
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_DN C2 199 0.52 1.73
LEE_LIVER_CANCER_E2F1_UP C2 60 0.60 1.73
ABRAHAM_ALPC_VS_MULTIPLE_MYELOMA_UP C2 26 0.61 1.73
LINDVALL_IMMORTALIZED_BY_TERT_DN C2 79 0.56 1.73
REACTOME_ANTIVIRAL_MECHANISM_BY_IFN_STIMULATED_GENES C2 64 0.66 1.73
ALTEMEIER_RESPONSE_TO_LPS_WITH_MECHANICAL_VENTILATION C2 125 0.60 1.73
OZANNE_AP1_TARGETS_UP C2 16 0.74 1.73
GRAHAM_NORMAL_QUIESCENT_VS_NORMAL_DIVIDING_UP C2 63 0.64 1.73
REACTOME_IL_3_5_AND_GM_CSF_SIGNALING C2 43 0.61 1.73
REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET_PRODUCTION C2 120 0.40 1.73
KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY C2 75 0.55 1.73
PID_GMCSF_PATHWAY C2 37 0.60 1.73
WANG_SMARCE1_TARGETS_UP C2 274 0.53 1.73
LEE_NAIVE_T_LYMPHOCYTE C2 19 0.67 1.73
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY C2 98 0.50 1.73
STEARMAN_LUNG_CANCER_EARLY_VS_LATE_DN C2 59 0.58 1.73
LINDGREN_BLADDER_CANCER_CLUSTER_2A_DN C2 137 0.55 1.73
REACTOME_SEMA4D_INDUCED_CELL_MIGRATION_AND_GROWTH_CONE_COLLAPSE C2 24 0.64 1.73
ZHU_CMV_24_HR_UP C2 93 0.60 1.73
ROSS_AML_WITH_AML1_ETO_FUSION C2 75 0.49 1.73
WANG_TARGETS_OF_MLL_CBP_FUSION_UP C2 42 0.53 1.73
YAMAZAKI_TCEB3_TARGETS_UP C2 173 0.51 1.73
SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM3 C2 68 0.53 1.72
PATTERSON_DOCETAXEL_RESISTANCE C2 28 0.64 1.72
HOLLEMAN_ASPARAGINASE_RESISTANCE_ALL_DN C2 24 0.74 1.72
BIOCARTA_FAS_PATHWAY C2 30 0.63 1.72
FRIDMAN_IMMORTALIZATION_DN C2 33 0.62 1.72
JEON_SMAD6_TARGETS_UP C2 23 0.67 1.72
PID_IL2_PI3K_PATHWAY C2 34 0.56 1.72
WESTON_VEGFA_TARGETS_12HR C2 33 0.64 1.72
GENTILE_UV_RESPONSE_CLUSTER_D1 C2 18 0.68 1.72
RIGGI_EWING_SARCOMA_PROGENITOR_UP C2 414 0.43 1.72
WU_HBX_TARGETS_3_UP C2 18 0.70 1.72
BAELDE_DIABETIC_NEPHROPATHY_DN C2 427 0.52 1.72
HOLLEMAN_ASPARAGINASE_RESISTANCE_ALL_UP C2 22 0.59 1.72
PID_SYNDECAN_1_PATHWAY C2 46 0.66 1.72
ZHENG_FOXP3_TARGETS_IN_T_LYMPHOCYTE_DN C2 36 0.67 1.72
PARK_APL_PATHOGENESIS_DN C2 49 0.60 1.72
DAVICIONI_TARGETS_OF_PAX_FOXO1_FUSIONS_DN C2 66 0.51 1.72
REACTOME_MHC_CLASS_II_ANTIGEN_PRESENTATION C2 89 0.54 1.72
SASAI_RESISTANCE_TO_NEOPLASTIC_TRANSFROMATION C2 49 0.67 1.72
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION C2 251 0.44 1.72
JISON_SICKLE_CELL_DISEASE_UP C2 180 0.54 1.72
ZHU_CMV_8_HR_UP C2 46 0.64 1.72
TAVOR_CEBPA_TARGETS_DN C2 30 0.58 1.72
WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_DN C2 65 0.62 1.72
WOTTON_RUNX_TARGETS_UP C2 21 0.57 1.72
LY_AGING_PREMATURE_DN C2 29 0.65 1.72
ZEMBUTSU_SENSITIVITY_TO_VINCRISTINE C2 17 0.64 1.72
PODAR_RESPONSE_TO_ADAPHOSTIN_UP C2 143 0.56 1.72
REACTOME_IL_2_SIGNALING C2 41 0.60 1.72
VISALA_AGING_LYMPHOCYTE_DN C2 19 0.67 1.72
REACTOME_NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCTION_COMPLEX C2 103 0.74 1.72
BIOCARTA_BCR_PATHWAY C2 34 0.60 1.71
HERNANDEZ_ABERRANT_MITOSIS_BY_DOCETACEL_2NM_UP C2 80 0.51 1.71
REACTOME_G_ALPHA_Z_SIGNALLING_EVENTS C2 43 0.54 1.71
DORN_ADENOVIRUS_INFECTION_48HR_DN C2 40 0.64 1.71
PID_ERBB1_DOWNSTREAM_PATHWAY C2 103 0.49 1.71
MCBRYAN_PUBERTAL_BREAST_4_5WK_UP C2 269 0.48 1.71
HOFFMANN_PRE_BI_TO_LARGE_PRE_BII_LYMPHOCYTE_DN C2 72 0.51 1.71
KEGG_SPLICEOSOME C2 124 0.61 1.71
TSAI_RESPONSE_TO_RADIATION_THERAPY C2 32 0.67 1.71
MARSON_FOXP3_TARGETS_STIMULATED_UP C2 29 0.70 1.71
TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_8D_UP C2 148 0.51 1.71
CROONQUIST_STROMAL_STIMULATION_UP C2 57 0.68 1.71
PID_FAK_PATHWAY C2 58 0.55 1.71
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_LOBULAR_NORMAL_DN C2 73 0.65 1.71
LAIHO_COLORECTAL_CANCER_SERRATED_UP C2 112 0.68 1.71
CAIRO_LIVER_DEVELOPMENT_UP C2 166 0.53 1.71
MCCABE_HOXC6_TARGETS_DN C2 21 0.58 1.71
BROWN_MYELOID_CELL_DEVELOPMENT_UP C2 161 0.51 1.71
FULCHER_INFLAMMATORY_RESPONSE_LECTIN_VS_LPS_DN C2 438 0.51 1.71
KEGG_GRAFT_VERSUS_HOST_DISEASE C2 36 0.70 1.71
GAVIN_FOXP3_TARGETS_CLUSTER_P3 C2 153 0.46 1.71
KEGG_PRIMARY_IMMUNODEFICIENCY C2 35 0.68 1.71
ODONNELL_TARGETS_OF_MYC_AND_TFRC_UP C2 81 0.55 1.71
REACTOME_PD1_SIGNALING C2 17 0.74 1.71
CHANG_POU5F1_TARGETS_UP C2 15 0.70 1.71
KUMAR_TARGETS_OF_MLL_AF9_FUSION C2 393 0.42 1.71
LEE_TARGETS_OF_PTCH1_AND_SUFU_UP C2 52 0.52 1.71
ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_DN C2 49 0.59 1.71
GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_UP C2 68 0.54 1.71
KORKOLA_TERATOMA_UP C2 15 0.74 1.71
WIERENGA_STAT5A_TARGETS_UP C2 209 0.46 1.71
ST_ERK1_ERK2_MAPK_PATHWAY C2 32 0.59 1.71
HASLINGER_B_CLL_WITH_13Q14_DELETION C2 23 0.67 1.71
MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_UP C2 249 0.43 1.71
HEIDENBLAD_AMPLICON_12P11_12_UP C2 33 0.59 1.71
BOYLAN_MULTIPLE_MYELOMA_C_DN C2 54 0.54 1.71
CHUNG_BLISTER_CYTOTOXICITY_DN C2 43 0.57 1.71
PID_INTEGRIN3_PATHWAY C2 43 0.61 1.71
PID_KIT_PATHWAY C2 52 0.54 1.71
BOYAULT_LIVER_CANCER_SUBCLASS_G123_UP C2 44 0.63 1.70
LEE_AGING_NEOCORTEX_UP C2 87 0.54 1.70
MCBRYAN_PUBERTAL_BREAST_3_4WK_DN C2 36 0.55 1.70
KAYO_CALORIE_RESTRICTION_MUSCLE_UP C2 94 0.51 1.70
ZHAN_MULTIPLE_MYELOMA_CD2_UP C2 43 0.54 1.70
MULLIGHAN_MLL_SIGNATURE_2_DN C2 272 0.46 1.70
OKUMURA_INFLAMMATORY_RESPONSE_LPS C2 180 0.46 1.70
LE_EGR2_TARGETS_UP C2 107 0.51 1.70
REACTOME_POST_CHAPERONIN_TUBULIN_FOLDING_PATHWAY C2 16 0.72 1.70
BHATTACHARYA_EMBRYONIC_STEM_CELL C2 85 0.56 1.70
JUBAN_TARGETS_OF_SPI1_AND_FLI1_DN C2 86 0.55 1.70
WEIGEL_OXIDATIVE_STRESS_BY_TBH_AND_H2O2 C2 35 0.65 1.70
MODY_HIPPOCAMPUS_PRENATAL C2 41 0.67 1.70
AMIT_SERUM_RESPONSE_240_MCF10A C2 56 0.55 1.70
GENTLES_LEUKEMIC_STEM_CELL_UP C2 28 0.65 1.70
KEGG_TYPE_I_DIABETES_MELLITUS C2 40 0.63 1.70
HAHTOLA_SEZARY_SYNDROM_UP C2 96 0.56 1.70
OKAMOTO_LIVER_CANCER_MULTICENTRIC_OCCURRENCE_UP C2 25 0.69 1.70
DELASERNA_MYOD_TARGETS_DN C2 56 0.53 1.70
BIOCARTA_MPR_PATHWAY C2 33 0.58 1.70
VALK_AML_CLUSTER_10 C2 32 0.61 1.70
LU_TUMOR_ANGIOGENESIS_UP C2 25 0.73 1.70
ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP C2 269 0.44 1.70
TENEDINI_MEGAKARYOCYTE_MARKERS C2 66 0.53 1.70
FARMER_BREAST_CANCER_CLUSTER_4 C2 19 0.81 1.70
GENTILE_UV_RESPONSE_CLUSTER_D6 C2 35 0.64 1.70
GAVIN_FOXP3_TARGETS_CLUSTER_P4 C2 98 0.49 1.70
CAIRO_PML_TARGETS_BOUND_BY_MYC_UP C2 23 0.67 1.70
GAJATE_RESPONSE_TO_TRABECTEDIN_UP C2 65 0.57 1.70
SIG_CHEMOTAXIS C2 45 0.52 1.70
BOHN_PRIMARY_IMMUNODEFICIENCY_SYNDROM_DN C2 40 0.55 1.70
LINDSTEDT_DENDRITIC_CELL_MATURATION_A C2 65 0.66 1.70
ROY_WOUND_BLOOD_VESSEL_UP C2 49 0.65 1.70
HINATA_NFKB_TARGETS_FIBROBLAST_UP C2 84 0.59 1.70
YANG_BREAST_CANCER_ESR1_DN C2 25 0.67 1.70
PID_INTEGRIN_CS_PATHWAY C2 26 0.65 1.69
PAPASPYRIDONOS_UNSTABLE_ATEROSCLEROTIC_PLAQUE_UP C2 52 0.65 1.69
PID_ALK1_PATHWAY C2 26 0.61 1.69
REACTOME_RESPONSE_TO_ELEVATED_PLATELET_CYTOSOLIC_CA2_ C2 81 0.54 1.69
DAVICIONI_MOLECULAR_ARMS_VS_ERMS_DN C2 177 0.48 1.69
SIG_PIP3_SIGNALING_IN_B_LYMPHOCYTES C2 36 0.62 1.69
REACTOME_PROTEIN_FOLDING C2 49 0.63 1.69
GRAHAM_CML_QUIESCENT_VS_NORMAL_QUIESCENT_DN C2 44 0.61 1.69
SCHAEFFER_SOX9_TARGETS_IN_PROSTATE_DEVELOPMENT_DN C2 45 0.59 1.69
VERRECCHIA_RESPONSE_TO_TGFB1_C1 C2 17 0.71 1.69
GAVIN_FOXP3_TARGETS_CLUSTER_T4 C2 90 0.58 1.69
TURASHVILI_BREAST_LOBULAR_CARCINOMA_VS_DUCTAL_NORMAL_UP C2 67 0.66 1.69
MCDOWELL_ACUTE_LUNG_INJURY_UP C2 45 0.65 1.69
ONO_AML1_TARGETS_UP C2 24 0.65 1.69
TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMAL_UP C2 44 0.64 1.69
HOLLMANN_APOPTOSIS_VIA_CD40_UP C2 194 0.50 1.69
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY C2 125 0.46 1.69
LEI_MYB_TARGETS C2 312 0.50 1.69
POS_HISTAMINE_RESPONSE_NETWORK C2 32 0.60 1.69
JIANG_AGING_CEREBRAL_CORTEX_DN C2 52 0.57 1.69
PID_TNF_PATHWAY C2 46 0.57 1.69
REACTOME_L1CAM_INTERACTIONS C2 83 0.46 1.69
Fisher test
% n# patients % n# patients p-value
General Clinicopathological variables
Age
≥65 years 53% (52/98) 47% (46/98)
<65 years 46% (45/98) 23% (23/98) 0.11
Gender
Female 29% (28/97) 14% (10/69) 0.04
Male 71% (69/97) 86% (59/69)
Etiology
HCV 58% (57/98) 26% (18/69) <0.0001
HBV 16% (16/98) 36% (25/69) 0.01
Alcohol 9% (9/98) 19% (13/69) 0.10
Others 13% (13/98) 16% (11/69) 0.66
BCLC stage
BCLC 0 or A 76% (74/98) 91% (63/69)
BCLC B or C 22% (22/98) 7% (5/69) 0.01
Blood tests
AFP levels (>100 mg/dL) 24% (23/96) 24% (16/67) 1.00
Albumin levels (<3.5 gr/L) 18% (17/95) 4% (3/68) 0.01
Bilirubin (>1 mg/dL) 53% (50/94) 28% (19/68) 0.00
Platelet count (<100,000/mm3) 29% (28/96) 12% (8/68) 0.01
ICF non ICF
Supplementary Table 5. Correlation of the immune-mediated cancer field with clinicopathological 
characteristics.
Variable
HR CI (95% low-high 
limits)
p-values
Vascular invasion 1.79 1.11-2.92 0.018
Multinodularity 2.67 1.56-4.58 <0.001
BCLC stage B or C
HCV etiology
Platelet count (<100,000/mm3) 2.23 1.32-3.78 0.003
Satellites
Gender
Albumin levels (<3.5 gr/L)
Tumor size (>3.5cm)
Immune-mediated cancer-field (ICF, current manuscript )

















Supplementary Table 7. 172-gene signatures of immune-mediated cancer field.
















































































CXCL13 ICF High Infiltrate
MS4A1 ICF High Infiltrate
CR2 ICF High Infiltrate
BANK1 ICF High Infiltrate
FCRL3 ICF High Infiltrate
C4orf7 ICF High Infiltrate
IGKV3D-11 ICF High Infiltrate
AIM2 ICF High Infiltrate
POU2AF1 ICF High Infiltrate
CCR7 ICF High Infiltrate
MMP9 ICF High Infiltrate
CD52 ICF High Infiltrate
TRBC1 ICF High Infiltrate
ITK ICF High Infiltrate
CCL21 ICF High Infiltrate
CCL19 ICF High Infiltrate
GZMK ICF High Infiltrate
BCL11B ICF High Infiltrate
LY75 ICF High Infiltrate
FYB ICF High Infiltrate
PRKCH ICF High Infiltrate
CD3D ICF High Infiltrate
TRBC2 ICF High Infiltrate
RGS10 ICF High Infiltrate
TRAC ICF High Infiltrate
TRAJ17 ICF High Infiltrate
TRAV20 ICF High Infiltrate
TRAF5 ICF High Infiltrate
DOCK10 ICF High Infiltrate
NLRC5 ICF High Infiltrate
RHOH ICF High Infiltrate
PVRIG ICF High Infiltrate
STAG3 ICF High Infiltrate
CD8A ICF High Infiltrate
GPR18 ICF High Infiltrate
RAC2 ICF High Infiltrate
LAPTM5 ICF High Infiltrate
WDFY4 ICF High Infiltrate
CD48 ICF High Infiltrate
CD2 ICF High Infiltrate
LTB ICF High Infiltrate
IRF4 ICF High Infiltrate
GIMAP7 ICF High Infiltrate
EMB ICF High Infiltrate
EMBP1 ICF High Infiltrate
DOCK11 ICF High Infiltrate
LCK ICF High Infiltrate
CST7 ICF High Infiltrate
CCL5 ICF High Infiltrate
CD53 ICF High Infiltrate
PRKCB ICF High Infiltrate
PTPRC ICF High Infiltrate














































Satellites 2.22 0.87-5.67 0.096
Albumin levels (<3.5 gr/L) 2.6 0.89-7.58 0.08
Tumor size (>3.5cm) 2.66 1.13-6.25 0.025
AFP (>100mg/dL) 2.28 0.96-5.56 0.064
Immune-mediated cancer-field (ICF, current manuscript ) 2.73 1.09-6.83 0.032
Variable p-value













Symbol Fold change p value  FDR q value
Up-regulated 
Gpnmb 5.01 0.00 0.00
Apoa4 4.86 0.00 0.00
Mmp12 4.05 0.00 0.00
Col1a2 3.9 0.00 0.00
Ly6d 3.88 0.00 0.00
S100a8 3.82 0.00 0.00
Ccl5 3.7 0.00 0.01
Mt2 3.61 0.00 0.03
Dpt 3.61 0.00 0.00
2010003K11Rik 3.57 0.00 0.00
Gstm3 3.45 0.00 0.00
Mt1 3.14 0.00 0.02
Ms4a7 3.11 0.00 0.01
Cpe 3.11 0.00 0.00
Ubd 3.1 0.00 0.00
Hamp2 3.07 0.00 0.00
Tuba8 3.06 0.00 0.00
Mtmr11 3.01 0.00 0.00
Mfsd2a 2.94 0.00 0.00
Tinag 2.92 0.00 0.01
Lum 2.91 0.00 0.00
Ccnd1 2.91 0.00 0.00
Akr1c18 2.87 0.00 0.04
Crtap 2.78 0.00 0.01
Cdkn2c 2.71 0.00 0.00
Ifi27l2b 2.69 0.00 0.00
Mmp2 2.67 0.00 0.00
Abcd2 2.67 0.00 0.00
Cyp7a1 2.62 0.00 0.02
Emp1 2.59 0.00 0.01
Cd24a 2.58 0.00 0.00
Col3a1 2.58 0.00 0.00
Igha 2.57 0.00 0.01
Prom1 2.56 0.00 0.01
S100a9 2.56 0.00 0.00
Lepr 2.53 0.00 0.00
Nek2 2.48 0.00 0.04
Ccdc80 2.44 0.00 0.00
Cdk1 2.39 0.00 0.00
2210013O21Rik 2.39 0.00 0.00
Ms4a6b 2.37 0.00 0.00
Tmem86a 2.36 0.00 0.01
Sparcl1 2.34 0.00 0.01
Rnf145 2.3 0.00 0.01
Hsd17b6 2.3 0.00 0.01
Cenpa 2.23 0.00 0.00
Supplementary Table 9. List of 300 differentially expressed 
genes in non-tumor liver parenchyma of DEN/CCl4 mice, 
treated with vehicle vs liver of healthy control mice (FC ≥1.5, 
FDR q<0.05).
Clec7a 2.2 0.00 0.00
Blnk 2.17 0.00 0.04
Cyp39a1 2.17 0.00 0.00
Slco1a4 2.15 0.00 0.04
Igkc 2.12 0.00 0.03
Sftpd 2.11 0.00 0.04
Olfml3 2.1 0.00 0.04
Lgals3 2.1 0.00 0.00
Jchain 2.1 0.00 0.03
Lgals4 2.08 0.00 0.00
Ttc39aos1 2.08 0.00 0.01
Col5a2 2.08 0.00 0.00
S100a6 2.08 0.00 0.02
Sgce 2.07 0.00 0.00
Klf4 2.06 0.00 0.03
Gpc1 2.04 0.00 0.02
Tceal8 2.02 0.00 0.00
Fstl1 2.01 0.00 0.00
Slc39a4 2.01 0.00 0.01
Pygb 1.98 0.00 0.04
Cbr3 1.98 0.00 0.01
Golm1 1.98 0.00 0.00
Lipo1 1.98 0.00 0.04
Coro1a 1.97 0.00 0.01
Lyve1 1.96 0.00 0.02
Sulf2 1.96 0.00 0.01
Spink1 1.96 0.00 0.05
Cbr1 1.95 0.00 0.00
Col6a3 1.95 0.00 0.01
Abcc4 1.95 0.00 0.00
Cyp4a31 1.93 0.00 0.02
Pf4 1.92 0.00 0.00
Il2rg 1.91 0.00 0.02
Vim 1.91 0.00 0.01
Serpina3g 1.9 0.00 0.01
Plat 1.89 0.00 0.01
Rhbdf1 1.89 0.00 0.01
Uap1l1 1.87 0.00 0.01
Ptprc 1.87 0.00 0.03
Hvcn1 1.86 0.00 0.02
Ltbp2 1.85 0.00 0.02
Fbn1 1.85 0.00 0.01
Defb1 1.84 0.00 0.04
Tpm1 1.84 0.00 0.00
Nipa1 1.84 0.00 0.00
Mgp 1.83 0.00 0.05
Itga8 1.83 0.00 0.02
Anxa1 1.83 0.00 0.00
Pdzk1ip1 1.82 0.00 0.04
Ccna2 1.82 0.00 0.00
Snhg1 1.82 0.00 0.04
Col1a1 1.81 0.00 0.02
H2-Eb1 1.8 0.00 0.00
Spc25 1.79 0.00 0.01
Klrd1 1.79 0.00 0.04
Cdt1 1.79 0.00 0.01
Armcx4 1.78 0.00 0.01
Map4k4 1.77 0.00 0.01
Abcb1a 1.77 0.00 0.05
Ect2 1.77 0.00 0.02
Itih5 1.76 0.00 0.01
Col6a2 1.75 0.00 0.01
Ms4a4b 1.75 0.00 0.04
Steap2 1.74 0.00 0.00
Nid1 1.74 0.00 0.01
Rnaseh2b 1.74 0.00 0.01
Icam1 1.74 0.00 0.04
Col4a2 1.74 0.00 0.01
Ctla2a 1.74 0.00 0.01
Mad2l1 1.73 0.00 0.01
Pecam1 1.73 0.00 0.02
H2-Ab1 1.73 0.00 0.03
Cyp3a44 1.73 0.00 0.05
Aim1 1.72 0.00 0.03
Csrp1 1.72 0.00 0.01
Glipr1 1.71 0.00 0.01
Plcg2 1.7 0.00 0.01
Cd52 1.7 0.00 0.02
Sh3bgrl3 1.7 0.00 0.01
Bicc1 1.7 0.00 0.02
Postn 1.7 0.00 0.01
Gdf10 1.7 0.00 0.00
Tmtc2 1.7 0.00 0.05
Psat1 1.69 0.00 0.01
Arl2bp 1.69 0.00 0.04
Acot9 1.69 0.00 0.05
Npdc1 1.69 0.00 0.03
Cmtm7 1.68 0.00 0.03
Cybb 1.68 0.00 0.04
Tmem164 1.67 0.00 0.01
Rdh9 1.67 0.00 0.00
Trim24 1.67 0.00 0.03
Sparc 1.67 0.00 0.00
Bax 1.66 0.00 0.00
Sirpa 1.66 0.00 0.03
Gm32031 1.66 0.00 0.00
Fmo4 1.65 0.00 0.02
Col4a5 1.65 0.00 0.02
Itpripl2 1.64 0.00 0.00
Tmem178 1.64 0.00 0.03
Hpse 1.64 0.00 0.02
Ppic 1.64 0.00 0.03
Csf2rb2 1.76 0.00 0.03
Laptm5 1.64 0.00 0.02
Myof 1.63 0.00 0.04
Gja1 1.63 0.00 0.01
Rab3d 1.62 0.00 0.02
St3gal5 1.62 0.00 0.02
Col4a1 1.62 0.00 0.00
Fam84b 1.62 0.00 0.01
Cdca3 1.62 0.00 0.04
H2-Aa 1.62 0.00 0.03
Cers6 1.61 0.00 0.04
Ptgr1 1.61 0.00 0.04
Plekho1 1.61 0.00 0.03
Fam46a 1.6 0.00 0.03
Zfp53 1.6 0.00 0.03
Chtf8 1.6 0.00 0.02
Mfge8 1.6 0.00 0.03
Pam 1.6 0.00 0.01
Cd9 1.6 0.00 0.04
Rhoc 1.59 0.00 0.00
Adcy7 1.59 0.00 0.00
Soat1 1.59 0.00 0.01
Slc6a8 1.58 0.00 0.02
Isyna1 1.58 0.00 0.03
Cxcl16 1.57 0.00 0.04
Ppap2c 1.57 0.00 0.02
Arhgap11a 1.57 0.00 0.03
Cygb 1.57 0.00 0.04
Mapkapk3 1.56 0.00 0.03
Setd7 1.56 0.00 0.01
Ctss 1.56 0.00 0.01
Tubb6 1.55 0.00 0.02
Phlda3 1.55 0.00 0.03
Lxn 1.55 0.00 0.02
Ptprcap 1.55 0.00 0.02
Tagln2 1.54 0.00 0.02
Pou2af1 1.53 0.00 0.02
Fam102b 1.52 0.00 0.01
Mndal 1.52 0.00 0.01
Mxra8 1.52 0.00 0.02
Ptpre 1.52 0.00 0.03
Nhlrc2 1.52 0.00 0.05
Wbp5 1.52 0.00 0.01
Iqgap1 1.51 0.00 0.04
Igsf8 1.51 0.00 0.04
Tbc1d10b 1.51 0.00 0.02
Slamf7 1.5 0.00 0.05
Down-regulated 
Hsd3b5 -14.54 0.00 0.01
Fitm1 -11.68 0.00 0.00
Susd4 -11.17 0.00 0.00
Cd74 1.59 0.00 0.03
Lect1 -6.72 0.00 0.00
Cyp7b1 -5.62 0.00 0.00
Olig1 -5 0.00 0.00
Serpina4-ps1 -4.27 0.00 0.02
Serpine2 -3.82 0.00 0.00
Adh6-ps1 -3.76 0.00 0.00
Tenm3 -3.72 0.00 0.00
Serpina12 -3.56 0.00 0.04
Lhpp -3.49 0.00 0.01
Nxpe2 -3.46 0.00 0.00
Avpr1a -3.25 0.00 0.01
Oat -3.11 0.00 0.00
Sucnr1 -2.81 0.00 0.00
Cela1 -2.7 0.00 0.00
1500017E21Rik -2.56 0.00 0.01
Slc1a2 -2.49 0.00 0.00
Cyp2u1 -2.42 0.00 0.00
Cyp2c37 -2.38 0.00 0.00
Rarres1 -2.37 0.00 0.00
Npr2 -2.34 0.00 0.00
Cml5 -2.28 0.00 0.01
Tex12 -2.26 0.00 0.01
Clstn3 -2.23 0.00 0.00
Wdr89 -2.18 0.00 0.01
Slc22a7 -2.17 0.00 0.05
Cyp4a12a -2.14 0.00 0.04
Pnldc1 -2.14 0.00 0.01
Dct -2.12 0.00 0.02
Nat1 -2.12 0.00 0.01
Tmem19 -2.09 0.00 0.00
Dpy19l3 -2.04 0.00 0.00
Fgf1 -2.04 0.00 0.00
Slco1a1 -2 0.00 0.04
Gna14 -1.98 0.00 0.00
Acad12 -1.97 0.00 0.00
Cyp2c54 -1.96 0.00 0.02
Slc17a3 -1.92 0.00 0.01
Pmm1 -1.92 0.00 0.00
Mogat1 -1.89 0.00 0.01
Cd163 -1.84 0.00 0.04
5033404E19Rik -1.83 0.00 0.01
Glul -1.83 0.00 0.04
Hdhd3 -1.82 0.00 0.02
Plbd1 -1.82 0.00 0.02
Eme2 -1.8 0.00 0.03
Tspyl4 -1.77 0.00 0.02
Rbm20 -1.76 0.00 0.04
Tsc22d1 -1.74 0.00 0.01
Gabrr1 -1.74 0.00 0.02
Pdilt -1.74 0.00 0.00
Cyp2j6 -1.74 0.00 0.02
Tuba4a -1.74 0.00 0.01
Gmppb -1.74 0.00 0.04
Rmdn2 -1.72 0.00 0.00
Pfkfb1 -1.71 0.00 0.04
Hrc -1.7 0.00 0.01
Zbtb21 -1.7 0.00 0.01
Zmat1 -1.67 0.00 0.03
Cav1 -1.66 0.00 0.02
Bmp4 -1.66 0.00 0.02
Slc22a3 -1.65 0.00 0.01
Nat8 -1.65 0.00 0.02
Capn8 -1.65 0.00 0.01
Inhba -1.64 0.00 0.04
Ldhd -1.63 0.00 0.00
Aatk -1.62 0.00 0.04
Srsf3 -1.62 0.00 0.02
Adrb3 -1.61 0.00 0.04
Hes6 -1.61 0.00 0.03
2610305D13Rik -1.6 0.00 0.05
3110070M22Rik -1.6 0.00 0.04
Mup5 -1.6 0.00 0.02
Tada3 -1.6 0.00 0.03
Fam228a -1.6 0.00 0.01
Ppapdc1a -1.59 0.00 0.04
Fzd7 -1.59 0.00 0.01
Mal2 -1.59 0.00 0.02
Ufl1 -1.59 0.00 0.02
Hyal1 -1.59 0.00 0.01
Slc6a7 -1.59 0.00 0.04
Khdrbs3 -1.58 0.00 0.01
Ces1e -1.57 0.00 0.01
Ces4a -1.57 0.00 0.04
Them7 -1.57 0.00 0.02
Id3 -1.56 0.00 0.05
Dusp1 -1.55 0.00 0.03
Angptl6 -1.55 0.00 0.02
Trpv4 -1.54 0.00 0.03
C1qtnf4 -1.53 0.00 0.05
Mapk1ip1 -1.53 0.00 0.02
Mfsd8 -1.53 0.00 0.01
Zfhx4 -1.52 0.00 0.02
C6 -1.52 0.00 0.05
Csrp3 -1.52 0.00 0.01
Pole4 -1.52 0.00 0.01
Poc1b -1.52 0.00 0.00
Snhg11 -1.52 0.00 0.00
1700001C02Rik -1.52 0.00 0.01
Chic1 -1.52 0.00 0.04
Sdr42e1 -1.51 0.00 0.02
Moxd1 -1.5 0.00 0.02
Ccdc185 -1.5 0.00 0.01
Nars2 -1.5 0.00 0.01
Supplementary Table 9. IPA analysis of genes upregulated (FC > 1.5, FDR <0.05) in livers of DEN/CCl4 treated with vehicle (compared with healthy control group).
TOP CANONICAL PATHWAYS
Name p value
Hepatic Fibrosis / Hepatic Stellate Cell Activation 2,54E-11 
Atherosclerosis Signaling 1,90E-06 
B Cell Development 7,23E-06 
Granulocyte Adhesion and Diapedesis 1,04E-05 
Dendritic Cell Maturation 1,10E-05
TOP DISEASE AND FUNCTIONS
Name p-value
Cancer 






Increased Levels of LDH 
Increased Levels of ALT 
Decreased Levels of Albumin 
2,88E-04 - 1,04E-29 
2,88E-04 - 1,04E-29 
2,09E-04 - 8,99E-22 
8,43E-02 - 3,38E-02
1,74E-01 - 7,08E-02
2,65E-04 - 5,10E-20 
2,52E-04 - 2,18E-18 
1,22E-03 - 1,22E-03
